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Myxovirus (influenza virus) resistance A (MxA) is an interferon regulated protein
responsible for a specific antiviral state against viral infection. Our lab has previously
shown that MxA is up-regulated by androgens in the normal prostate epithelial cells;
however, there is no known role for MxA in cancer. Meta-analysis of different expression
databases (e.g. NCBI GEO and Oncomine) suggested a strong inverse association
between MxA expression and prostate cancer. To confirm these studies, we performed
immunohistochemistry on normal prostate and prostate cancer tissues. Our results
revealed that MxA expression was indeed decreased in cancerous as compared to normal
prostate, indicating that MxA could be transcriptionally down-regulated in cancer.
Previous studies indicated that MxA down-regulation could be due to a specific
polymorphism in the proximal MxA promoter at position -88. This single nucleotide
polymorphism G>T (rs2071430) is involved in modifying the gene expression and
interestingly, it harbors an interferon-stimulated response element (ISRE) that is required
for expression in response to interferons. The "T" allele restores whereas the "G" allele
attenuates ISRE binding, resulting in increased or decreased MxA expression,
respectively. Based on these observations we hypothesized that decreased expression of
MxA in prostate cancer could be due to the rs2071430 polymorphism. We investigated
this polymorphism in genomic DNA from equal number of disease free and prostate
cancer samples. The results provide evidence that the GG genotype (low promoter
activity) is higher in PCa (72%) as compared to normal (58.6%). The TT genotype (high
activity) was higher in normal (5.7%) compared to PCa (2.4%) p<0.05. No TT genotype
was observed in Caucasian normal samples. Our results, for the first time demonstrate
that MxA is down-regulated in prostate cancer possibly at the transcriptional level due to
ISRE polymorphism in the promoter region.
Recent studies have indicated that the antiviral protein MxA may have alternative
functions including modulating apoptosis and inhibiting metastasis. The second aim of
this study was to investigate the functional significance ofMxA in prostate cancer.
Results showed that MxA is regulated through the classical IFN pathway as well as by
androgens and serum factors. DU145 cells lacking MxA showed a significant increase in
proliferation, migration and a decrease in apoptosis as compared with the vector control,
which suggests that MxA may play an important role as a tumor suppressor in prostate
cancer. MxA may induce apoptosis in prostate cancer cells and sensitize them to
chemotherapeutic drugs thus making MxA a promising target for gene therapy on
prostate cancer.
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The link between cancer and viruses has been one of the pivotal discoveries in cancer
research where viruses have been estimated to be involved in approximately 10-15% of
all cancers. Recent studies provide experimental and epidemiological data that have
correlated prostatitis and viral and/or bacterial infections with increased PCa risk. Results
are consistent with the hypothesis that the anti-viral pathways could be major
determinants of cancer initiation. Most, if not all, anti-viral pathways are regulated by
interferons (IFN). IFN-induced pathways are significantly down-regulated in cancers.
Evidence that viral pathways are de-regulated in prostate cancer comes from the studies
demonstrating that RNASE L is de-regulated/ mutated in hereditary prostate cancer. Our
lab showed that androgens primarily regulate the immune inflammatory pathways in
normal prostate epithelial cells including MxA. Myxovirus (influenza virus) resistance A
(MxA), is an interferon regulated antiviral protein. MxA may have a role in prostate
cancer initiation by possibly interfering with viral infection in pre-initiation stages of
PCa. Our broad hypothesis is that MxA expression is associated with prostate cancer (i.e.
the viral response pathway is not functional in prostate cancer). In searching for evidence
to support our hypothesis we determined that MxA expression was decreased in prostate
cancer (NCBI- GEO Database). This evidence establishes a clinical association/link
between MxA and prostate cancer. The objective of the current project was to determine
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the expression/function ofMxA and to understand its molecular mechanism of action in
prostate cancer. We addressed this objective with the following specific aims:
1. Investigate the association of the MxA Polymorphism (rs2071430) with
prostate cancer.
2. Determine the mechanism by which MxA is regulated in prostate cancer
and its functional significance.





Prostate cancer is the second most common type of cancer among men in the
United States. According to American Cancer Society there will be an estimated 238,590
new cases of prostate cancer in 2013 and 29,720 deaths, which is a significant increase
since 2009 (/).
The prostate is an exocrine gland of the male reproductive system that is located
directly under the bladder and in front of the rectum as illustrated in Appendix Figure 1.
Prostate cancer is an androgen-driven cancer which is a trait that can be used both for
screening purposes and as a target for early therapies. Early prostate cancer grows locally
within the prostate, often for many years. Eventually, prostate cancer extends outside the
prostate, and spreads in three ways (i) by invading into neighboring tissues (ii) by
spreading through the lymph system of lymph nodes and lymph vessels and (iii) by
traveling to distant tissues through the blood (metastasis) (2).
There are four distinct stages of prostate cancer as seen in Appendix Figure 2. In
stage I, prostate cancer is confined only in the prostate gland area. Stage I prostate cancer
is microscopic and difficult to diagnose (2). In stage II, the prostate tumor has grown
inside the prostate but hasn't yet extended beyond it. Stage III prostate cancer has spread
outside of the prostate minimally. Prostate cancer in stage III may involve nearby tissues
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(7). In stage IV, the cancer has metastasized outside of the prostate to other tissues. Stage
IV prostate cancer commonly spreads to lymph nodes, the bones, liver, or lungs. Prostate
cancer stage helps determine the optimal treatment, as well as prognosis (2). Accurately
identifying the prostate cancer stage is extremely important and one of the most common
ways to screen and diagnose prostate cancer is by PSA screening.
Prostate specific antigen (PSA) is a glycoprotein that is produced by the prostatic
epithelium (3). An increase in PSA can be an indication of abnormal prostatic growth and
is used in some countries as a non-invasive means of screening for prostate cancer;
normally a threshold of 4 ng/ml is used (4). The concentration of PSA that is considered
to be normal depends greatly on the age of the patient as well. There are several
controversies regarding screening for prostate cancer using PSA, and the screening
programs vary greatly from country to country (5, 6).
For diagnostic purposes, regular PSA measurements are used in conjunction with
digital rectal examination and trans-rectal ultrasound guided biopsy of the prostate (7).
The introduction of PSA screening programs in the late 1980s lead to a dramatic increase
in the number of cases diagnosed annually, especially of patients with a low-risk cancer
(8). This has meant a shift from diagnosing mainly high risk, late stage prostate cancer to
detecting low-risk disease, which of course improves the chances of successful treatment.
The primary concern is over diagnosis, which is leading to over treatment of cancer that
would not become symptomatic (9). Treatment of prostate cancer depends on the stage of
the diagnosed tumor and of the age and life expectancy of the patient. Treatment for
prostate cancer can be: radical prostatectomy, radiotherapy, hormonal therapy or a
combination ofthem (7) .
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The exact cause of prostate cancer is not yet known but there are certain risk
factors linked to the disease. Numerous studies have been conducted on the genetic
etiology of the disease. There is emerging evidence that prostate inflammation may
contribute to prostatic carcinogenesis. Evidence from genetic and molecular studies also
supports the hypothesis that prostate inflammation and/or infection may be a cause of
prostate cancer (10). Epidemiological data have correlated prostatitis, sexually
transmitted diseases, as well as viral and bacterial infections with increased risk of
prostate cancer (77, 12).
2.1.1 Prostate cancer and genetic factors
Over the past years multiple pieces of evidence support the notion that genetics
plays a role in prostate cancer susceptibility and pathogenesis. The evidence also
indicates that the genetic basis of prostate cancer is far more complex than what was
initially anticipated. To study the link between prostate cancer (PCa) and genetics; large
families have been studied in which prostate cancer clusters together. Early observations
were made in large families studied in Utah, but the first description of familial
aggregation of prostate cancer was reported as far back as 1956 (73).
Several published studies have illustrated an increased risk for prostate cancer
among men with a family history for prostate cancer. In 2003, Bruner et al. (14)
published a meta-analysis of 16 case-control studies and eight cohort studies supporting
this previous theory. The term "family history" was defined as cases where a father,
brother, any first- or second-degree relative or other relative had been affected by prostate
cancer (14). Pooled Risk ratios (RRs) for men with any affected family member, one
affected first-degree relative and one affected second-degree relative were 1.9 (95% CI,
1.6-2.2), 2.2 (95% CI, 2.1-2.4) and 1.9 (95% CI, 1.6-2.3), respectively. These results
illustrate familial risk of prostate cancer. Further increases in risk ratios (RR) were also
consistently observed when (i) more than one relative was affected, (ii) the closeness of
the affected relative to the unaffected individual increased, and (iii) the age of onset of
the affected decreased. Taken together, this is strong evidence for a genetic component in
familial prostate disease.
Although more than 40% ofprostate cancer cases are estimated to be an effect of
genetic variation (15), rare, highly penetrant genes probably account for a minority of
prostate cancer cases. Mutations in high-penetrance susceptibility genes increase the risk
of cancer several fold, and tumors with such mutations are often called hereditary
cancers. So far; there have been high-risk candidate genes identified to include;
HPC/ELAC2 on 17p, MSR1 on 8p22-23, and RNASEL on Iq25 (16-18).
RNASEL is a constitutively expressed latent endoribonuclease that mediates the
antiviral and pro-apoptotic activities of the interferon inducible 2-5A system (19). Once
activated by interferon, cells containing a functional RNASEL gene produce an enzyme
that degrades single-stranded RNA, leading to apoptosis (20). Defects in the RNASEL
gene have were shown to result in reduced immunity to viral infections and cancer (21).
A genome-wide scan for linkage in prostate cancer families found evidence for a prostate
cancer susceptibility locus on chromosome lq24-25 (22). In 2002, Cartpen et al.
identified RNASEL as a candidate gene for the HPC1 locus through a positional cloning
and candidate approach. A truncating mutation (E265X) and an initiation codon mutation
(Mil) were reported to co-segregate within two specific prostate cancer families (16). In
addition to the rare mutations, a number of relatively common RNASEL variants have
been associated with prostate cancer risk.
There is some confirmatory evidence for the association between variants of
RNASEL and prostate cancer risk (23), but other studies have shown no association (24-
26). In summary, the role ofRNASEL in the pathogenesis of prostate cancer is still
unclear, due to inconsistencies in the association studies. However, reported in a review
from 2004, "it is tempting to speculate that genetic variants of the RNASEL gene
increase the risk for prostate cancer only in the presence of some environmental factor
(e.g. viral infection) that may vary between different study populations" (27).
2.1.2 Polymorphism and prostate cancer
The remainder of the genetic influence is most likely mediated by more common
genetic variants or polymorphisms. Low penetrance polymorphisms increase the risk of
cancer only modestly, but the prevalence of such polymorphisms may be higher than the
prevalence of mutations in high penetrance susceptibility genes, and thus their overall
existence could prove to be substantial (25). The list of these variants is long, but the
major pathways currently under investigation include those involved in DNA repair (29-
31), carcinogen metabolism, the action of androgens (28, 52)as well as inflammation
pathways (33-35). Numerous polymorphisms have already been suggested to be
associated with the risk of prostate cancer one in particular being a part of the
inflammation pathway. One approach is to elucidate whether functional polymorphisms
in genes that regulate inflammatory processes, such as cytokines, confer altered risks for
developing cancer or are potential prognostic factors.
2.2 Inflammation and cancer
Various carcinomas (including cancers of the liver, bladder, colon, stomach, and
esophagus) have been shown to arise from areas of infection and inflammation. Over
15% of all malignancies worldwide are attributable to infectious agents, and
inflammation is a major component of these chronic infections (36). Colon cancers
arising in individuals with inflammatory bowel disease (e.g. chronic ulcerative colitis or
Crohn's disease) and stomach cancers caused by chronic Helicobacter pylori infection are
among the most intensively studied and well established types of cancer associated with
inflammation of different origins (37).
Inflammation involves the induction of complex, coordinated chemical signals
and associated physiological processes following injury that promote "healing" of
damaged tissues. Early responses include increases in vascular permeability and
activation, together with the directed migration of leukocytes towards the site of injury.
This is where the ground-work is laid for the formation of a new extracellular matrix. The
directional migration of leukocytes is mediated by secreted chemokines that form a
concentration gradient towards the site of inflammation. The extracellular matrix
provides the structure upon which cells can migrate, proliferate, and regenerate new
tissue and a vascular network. In the later stage of the inflammatory response, the
macrophages are the dominant cell type, orchestrating and directing the healing process.
Normally, inflammation is a self-limiting process due to the production of anti-
inflammatory cytokines that buffer the effect of pro-inflammatory cytokines. The
cytokine/chemokine pattern persisting at the inflammatory site is important in the
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development of chronic disease. Dysregulation of any of the cooperating factors can lead
to prolonged inflammation with chronic exposure to cytotoxic mediators (37).
Chronic inflammation can be caused by a variety of factors, including bacterial,
viral, and parasitic infections, chemical irritants, and non-digestible particles. Oftentimes
the underlying cause of chronic inflammation is not known. The longer the inflammation
persists, the higher the risk of associated carcinogenesis (38). At the site of inflammation,
caused by either wounding or infection, phagocytic cells (e.g. neutrophils and
macrophages) generate reactive oxygen and nitrogen substances, but these cells also
synthesize and secrete large quantities of growth factors and a number of potent
angiogenic factors, cytokines, and proteases, all of which are important mediators in the
tissue regeneration, but can also potentiate neoplastic tumorigenesis.
2.2.1 Inflammation and prostate cancer
Although it has been established that chronic inflammation plays a causative role
in the development ofmany human cancers, the contribution of inflammatory processes
to the development of prostate cancer has not been extensively studied. However, data
from epidemiological, genetic and molecular pathology studies have been accumulating
recently and suggest that inflammatory processes are also involved in the development of
prostate cancer. The chronic inflammatory microenvironment, characterized by the
accumulation ofmacrophages and lymphocytes, is extremely common in the tissue
stroma and epithelium of the prostate and may support both the initiation and progression
of prostate cancer (39).
Due to the combined findings ofhigh proliferation indices and inflammatory
infiltrations seen in prostate lesions, the term proliferative inflammatory atrophy, or PIA,
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was introduced (40). The underlying causes of PIA lesions are still not clearly
understood, but they may arise either as a consequence of epithelial damage (from
infection, ischemia, or toxin exposure) or as a direct consequence of inflammatory
oxidant damage to the epithelium (41). Accumulating evidence from morphological,
immunohistochemical and genetic studies have provided evidence for the concept that
PIA lesions may be precursors to prostate cancer, partly because the vast majority of such
lesions are found adjacent to or near early adenocarcinomas or high grade prostatic
intraepithelial neoplasms, or both (40, 42, 43). Further support for the hypothesis comes
from the fact that PIA shares several molecular alterations found in both prostate
intraepithelial neoplasia (PIN) and prostate cancer (40).
In addition, chromosome 8 abnormalities, which are common occurrences in
prostate cancer, were found in areas ofPIA lesions. Acquired chromosome 8
abnormalities have been noted in about 1% ofnormal prostate tissue, 4% of PIA lesions,
and about 6% of adenocarcinomas (44). Other studies have reported p53 mutations in 5%
of PIA lesions, a rate similar to that seen in high-grade PIN, compared to 20% of prostate
cancer cases (45). Thus, these are genetic changes that are associated with PIN and
prostate cancer. Even though PIA lesions may be an early histological precursor to
prostate cancer, it is important to note that some studies have not found an association
between PIA and prostate cancer (46). Moreover, not all cancers occur within or in the
vicinity of PIA. In fact, PIA may simply indicate an intraprostatic environment that
favors and leads to prostate cancer development as seen in Figure 3.
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2.2.2 Prostatitis and prostate cancer
Prostatitis, which is the inflammation of the prostate, is a common urological
disorder worldwide; 2-10% ofmen experience it during their lifetime {47). The clinical
presentation is characterized by uncomfortable symptoms, such as dysuria, and rectal and
suprapubic pain (48). Prostatitis is classified into four categories: I, acute bacterial; II,
chronic bacterial; III, chronic nonbacterial/chronic pelvic pain syndrome; and IV,
asymptomatic prostatitis. Both acute bacterial prostatitis (which is usually caused by
Escherichia coli) and chronic bacterial prostatitis (caused by E. coli and several other
infectious agents) are normally treated with antibiotics. Chronic non-bacterial
prostatitis/chronic pelvic pain syndrome, is the most common form, affecting 90-95% of
patients with prostatitis. Men with this type of prostatitis may experience symptoms for
weeks to years, and current therapy has limited success in alleviating the pain that the
patients experience. Asymptomatic prostatitis is a histological diagnosis of prostate
inflammation that is found subsequent to pathological examination of the prostate tissue.
This category is found in a significant number of patients and epidemiologic studies have
estimated its prevalence to be as high as 32.2% in a population ofmen with elevated
Prostate Specific Antigen (PSA) (49). The PSA test has been widely used to screen men
for prostate cancer. It is also used to monitor men who have been diagnosed with prostate
cancer to see if their cancer has recurred after initial treatment or is responding to therapy
(3).
Several case-control studies have investigated the association between prostate
cancer and prostatitis, with variable results. In 2002, Dennis et al. performed a meta-
analysis of 11 case-control studies that evaluated the possible relationship between
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prostatitis and prostate cancer. The meta-analysis found an increased risk of prostate
cancer among men with a history of clinical, or symptomatic prostatitis (OR=1.6; 95%
CI, 1.0-2.4), particularly in population-based case-control studies (OR=1.8; 95% CI, 1.1-
3.0) (50). There are numerous complexities involved in diagnosing prostatitis and the
risks for potential recall or detection bias when performing association studies. Those
complexities in the association between prostatitis and prostate cancer make the analyses
problematic. The results could reflect an effect of detection bias, since patients with
prostatitis may be more likely to be monitored by a urologist and thus more likely to be
screened for prostate cancer, or the results could reflect a recall bias, because patients
with prostate cancer may try to remember more about potential exposure to prostatitis
than the controls (50).
Epidemiological studies investigating the possible association between prostatitis
and prostate cancer have relied on patient reports for information on prostatitis history.
Therefore, there are serious problems in using studies of this type to identify valid
relationships between category IV prostatitis and prostate cancer. The reason why
inflammation leads to symptoms in some men but not others is not known. It is possible
that a distinguishing feature between symptomatic and asymptomatic prostatitis may be
the anatomical localization of the prostatic inflammation. Inflammation in the peri-
urethtral region, or transition zone, may be more likely to manifest in urinary symptoms
and pain than inflammation in the outer areas of the gland, or the peripheral zone, where
prostate cancer more commonly develops (27).
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Two epidemiological studies have illustrated that the prevalence of prostatitis
correlates with the prevalence of prostate cancer worldwide, with rates of prostatitis and
prostate cancer being much higher in North America than in Asia (48, 51).
Sexually transmitted infections (STIs) have also long been hypothesized to
increase the risk for prostatitis and prostate cancer. STIs are theorized to increase the risk
of prostate cancer by causing inflammation of the prostate, which may in turn lead to the
initiation of carcinogenesis (52). These STIs often times are viral in nature.
2.2.3 Viruses and cancer
Because it was shown that nearly 15-25% of cancers have a viral etiology, it is
important to understand the association between viruses, anti-viral pathways and cancer
(53). Several viruses have been linked to many types of cancer. The Epstein-Barr virus
has been linked with Burkitt's lymphoma (54). The Hepatitis B and C viruses have been
linked with liver cancer in people with chronic infections. HTLV-I, a retrovirus, has been
linked to T-cell leukemia (55) illustrated in Figure 4. Papilloma viruses have been linked
with cervical cancer and skin cancer; however, five studies investigating possible
associations between human papilloma virus (HPV) and prostate cancer have found
variable results. The results rangie from no association to statistically significantly higher
risks for HPV-seropositive men (27).
A meta-analysis study by Taylor et al. also examined the associations between
HPV infection and prostate cancer risk detected in ten studies using either serological or
PCR based evidence of HPV infections. The results showed an odds ratio (OR) of 1.39
(95% CI, 1.13-1.71). Notably, while HPV is known to be an oncogenic virus, its
influence on prostate carcinogenesis may be independent of inflammation.
14
Several studies have investigated the presence of infectious agents in prostate
tissue. Various viruses and bacteria were found, but the results have not been very
consistent, possibly due to methodological differences (such as differences in the tissue
handling and detection methods), or possible contamination from agents in areas close to
the prostate (56). It is also worth noting that STIs detected in the prostate cancer tissues
could have been acquired after the initiation of carcinogenesis. Furthermore, the failure to
detect infectious agents in the prostate tissue does not necessarily mean that these agents
do not play a role in prostate carcinogenesis, as some may be cleared after causing
damage (41). Human papilloma viruses, human herpes virus-8, Herpes simplex virus-2,
cytomegalovirus and Epstein-Barr virus are some of the agents that have been found in
prostate tissue(2 7).
Xenotropic murine leukemia virus-related virus (XMRV) was previously
discovered in a subset of men with prostate cancer and was thought to be the first
gammaretrovirus known to infect humans (19); however, researchers found that XMRV
replicated easily in cultured human prostate tissue, but not in other types ofhuman
tissues. There was an association of this virus with malignant prostatic tissues (57);
however, it has been established that virus detected was actually contracted through RNA
that had been contaminated with cells which produce high titer of the XMRV virus.
22Rvl cells were derived from serial passage through nude mice xexnographs (56, 58).
Discovery ofXMRV followed investigations of the role of the antiviral enzyme RNase L
in hereditary prostate cancer. A R462Q certain mutation in RNASEL is associated with
increased XMRV viral infection in prostate cancer (79). RNase L is required for a
complete interferon (IFN) antiviral response against XMRV as well as other viruses.
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The immune system protects the organism from diseases by identifying and
killing pathogens or tumor cells. Pathogens that can be detected range from viruses to
multicellular parasitic worms. According to the functional mechanism and effects,
immunity can be classified into two types, innate immunity and adaptive immunity (59).
The innate immunity provides non-specific defenses against pathogenic challenges but
does not confer long-lasting effects to these protections, while adaptive immunity,
activated by the innate immune system, generates highly specialized cells and systematic
processes that eliminate invading pathogens and exhibit a memory response upon
reinfection (59).
Recently a third form of immunity was discovered and termed 'intrinsic
immunity'. It is characterized by constant expression of genetically coded proteins
specifically targeted against eukaryotic retroviruses (60, 61). A major function of the
vertebrate innate immune system is the recruitment of certain immune cells to infection
sites through specialized small proteins called cytokines/chemokines, which act as the
signaling mediators between the cells (59).
2.3 Interferons/Antiviral Pathways
The interferon (IFN) system plays an essential role in the first line of defense
against inflammation and viruses. Many cell types produce and secrete IFN alpha and
IFN beta in response to many viral infections (62) as seen in Figure 5. This signals the
presence of an invading virus and acts in a paracrine manner as a warning signal to
neighboring cells. There are many types of interferons depicted in Figure 6. Our focus is
mainly on Type I IFN. These interferons bind to the IFNARl receptors. The binding of
Type 1 IFN to this receptor complex triggers the intracellular Jak/STAT pathway.
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Activation of the JAK/STAT signaling pathway constitutes an important regulatory
mechanism by which host cells inhibit viral infections. The central transcriptional
activators of this pathway are the STAT proteins. The STAT-1, STAT-2, and STAT-3
proteins are important regulators of the innate immune responses to infections by a
variety ofRNA and DNA viruses (63-66). The activation of this signaling cascade then
leads to the activation and enhanced expression ofmore than 300 known genes (67-69).
These different actions converge to produce the "antiviral state/response". There are
three major antiviral pathways, OAS, PKR, and MxA that are activated to produce an
antiviral state as depicted in Figure 7.
Overall, results suggest that the anti-viral pathways (interferon) could be major
determinants of cancer initiation. Dysfunction of the immune system has been
documented in many types of cancers to include melanoma (70). The precise nature and
molecular basis of immune dysfunction in cancer is not well defined. Defects in
interferon signaling represent mechanisms of immune dysfunction in cancer (70). Cancer
inhibits the immune system by various cellular and molecular mechanisms.
Dysfunction of the immune system arises during the early stages of cancer and
throughout progression to metastatic disease (71). There are indications that suggest that
normally, the interferon pathway is important in fighting off cancers because of studies
done on mouse models in which the pathway was purposely disrupted. In those studies
the mice developed spontaneous tumors at higher rates than in normal mice with
functional interferon signaling. This evidence suggests that the immune system is able to
stop many cancers when they initially begin and the interferon pathway may harbor a
general immune defect in many types of cancer (72).
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2.3.1 Interferons
Among the cytokines, interferons (IFNs) are the earliest discovered examples and
represent a large family of proteins exhibiting strong antiviral functions (73-75). The IFN
family is mainly comprised oftwo types of related cytokines: Type I IFNs and Type II
IFN (76). The Type I group consists of 7 classes, IFN-a, IFN-p, IFN e, IFN-k, FN-co,
IFN-8, and IFN-t. IFN-a has 13 subspecies and other IFNs only have one (77-79). IFN-a,
IFN-P, IFN-e, IFN-k and IFN-co are found in humans whereas IFN-8 and IFN-x are
described only in pigs and cattle, respectively (75). Type II IFN contains only IFN-y.
Type I and Type II IFNs are structurally distinct: they bind different receptors and are
encoded by separate chromosomal loci. Genes encoding Type I IFNs are clustered on
human chromosome 9 and Type II IFN genes are located on chromosome 12 in humans
(74).
The most prevalent interferon present in epidermal keratinocytes is IFN kappa.
IFN kappa also belongs to the Type I IFN and displays approximately 30 % homology to
other members ofthe interferon family (78). It has been reported that IFN-kappa signals
through the canonical type 1 interferon receptor complex (consisting of the two subunits
IFN-alphaRl and IFN-alphaR2) (80).
In recent years, another class of IFN-like molecules have been discovered and
named IFN-X1, IFN-A2 and IFN-A3 (also known as interleukin (IL)-29, IL28A and
IL28B) (81, 82). Genes encoding IFN-X.S are clustered on human chromosome 19 (82).
IFN-A,s have a similar but independent functional mechanism from Type I IFNs and are
sometimes referred as Type III interferons (81-83).
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In the IFN family, IFN-a, IFN-p and IFN-y are currently the most well-
characterized members. IFN-a, IFN-p, IFN-k and IFN-X, are the mediators for the
expression ofMx proteins. Therefore these Type I IFNs will be discussed in the
following sections.
2.3.2 Interferon functions
Type I IFNs are expressed at a low level in almost all cell types, although
hematopoietic cells are the main producers of IFN-a while IFN-p is mostly secreted in
fibroblasts (IFN-a and IFN-p were therefore originally termed leukocyte and fibroblast
IFN, respectively) (84). Generally speaking, viruses or double-stranded (ds) RNA can
induce human cells to produce IFN-a and IFN-P, and the ratio of the expressed IFNs
varies by the organism, tissue, and viral species. IFN- a and IFN-p are mainly involved in
innate immune response against viral infection. Some IFN-a species also exhibit other
functions such as anti-proliferation and stimulation of cytotoxic activities of natural killer
(NK) cells and T cells and up-regulation of major histocompatibility complex (MHC)
class I antigen expression in cells (74, 82, 85).
Major production of IFN-7 takes place in CD4+ T helper cell type 1 (Thl)
lymphocytes and CD8+ cytotoxic lymphocytes when these cells are stimulated with
specific antigens or mitogens such as staphylococcal enterotoxin A or B, during the
adaptive immune response (84, 86). IFN-y is also secreted by NK cells, B cells, NKT
cells and possibly professional antigen-presenting cells (APCs) (87). The most
distinguishing feature of IFN-y from other IFNs is its versatile immunomodulatory
activity, although IFN-y is also involved in the immediate cellular response to viral
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infections. This activity directly affect Thl-type response development, B cell promotion
and local leukocyte endothelial interactions (88). Other important functions of IFN-y
include macrophage stimulation, NK cell promotion and up-regulation of the Class I & II
antigen presentation pathways in normal cells (89-91).
As a relatively new member of the IFN family, IFN-X has not yet been intensively
studied. It is typically co-expressed with type I IFNs by virus infected cells and has
antiviral activity against certain viruses that may, or may not, be suppressed by other
Type I IFNs, but in a similar way as Type I IFNs (74, 81, 92, 93).
2.3.3 Induction of interferon expression
The induction of IFN expression is regulated at the transcriptional level. For type
I IFNs, the best understood example for regulation is IFN-p. The IFN-P gene (IFNB)
promoter can interact with several transcription factors that cooperatively enhance the
IFNB transcription level (83). Of these transcription factors, interferon regulatory factor 3
(IRF-3) is thought to play the central role (94). Phosphorylation is required for IRF-3
activation.
Phosphorylated IRF-3 subsequently dimerizes and translocates into the nucleus to
cooperate with the transcriptional activator CREB-binding protein (CBP) and initiate
IFNB transcription. Another IRF family member, IRF-7, is also an important enhancer
which is utilized by the majority of INF-a promoters and is absolutely essential for IFN-a
expression. Unlike the constitutive expression of IRF-3, IRF-7 gene is IFN inducible
(95). Therefore, IFNB is transcribed in the early response, whereas IFN-a species are
expressed in relatively higher amounts but with delayed kinetics (95, 96). Two essential
partners of IRFs, nuclear factor kB (NF-kB) and activated protein-1 (AP-1, ATF-2/cJun
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particularly), are promoted as a more general stress response. They work together to
enhance IFNB transcription (83).
Induction of IFN-y expression appears to be more complex, as different pathways
are found in distinct cell types. On the cellular level, IFN-y production can be stimulated
by cytokines secreted by APCs, mostly IL-12 and IL-18, and negatively regulated by IL-
4, IL-10, transforming growth factor-p (TGF-P) and glucocorticoids (97-102). On the
genetic level, transcription factors such as YY1, nuclear factor of activated T cells
(NFAT), AP-1, NF-kB and signal transducer and activator of transcription proteins
(STATs) are found to bind the IFN-y gene (IFNG) promoter regions (103-108). Like type
I IFNs, positive feedback effect also exists as an important up-regulatory means in IFN-y
induction (87).
The induction of IFN-A, expression is overall similar to that of Type I IFNs. IFN-X,
gene transcription is also controlled by the IRF and NF-kB pathways when viral or other
PAMPs are present (109). It was also shown that IFN-X1 induction is largely dependent
on IRF-3 as with IFNB, whereas IFN-A2/3 expression mainly relies on IRF-7 as in the
case of INF-a. Moreover, IFN-X2/3 has delayed kinetics in comparison to IFN-M in the
immune response, which is analogous to the later response of INF-a compared to INF-P
(110).
Despite these similarities, however, the induction of IFN-A-s has also been
reported to possess substantial differences from that ofType I INFs. Firstly, IFN-X.S and
Type I IFNs are not always expressed in the same cell types. Exceptions are found in
macrophages which express Type I IFNs but not IFN-X.1 in response to influenza A virus,
while under the same conditions, human alveolar type II epithelial cells produce IFN-M
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but not IFN-P (111). Secondly, distinct from the cooperative manner of transcription
factors in the Type I IFN promoter activation, IRF and NF-kB regulate IFN-A.1 induction
independently, as the binding sites for IRF and NF-kB have been found spatially
separated on the IFN-M gene promoter (112). In addition, NF-kB seems to be the key
controller of IFN-X, production, rather than IRFs that play dominant role in IFN-a/p
expression (113).
2.3.4 Interferon-induced signaling pathways
In the immune response, secreted IFNs bind membrane receptors and initiate
signal transduction pathways that result in the expression ofnumerous IFN-stimulating
genes (ISGs). Type I, II and III IFNs bind to distinct membrane receptor complexes as
illustrated in Figure 9. Each one of the receptor chains interacts with a member of the
Janus activated kinase (Jak) family (114, 115). The Jak-STAT pathway was the first
signaling pathway shown to be activated by IFNs (116-119). The models of the IFN-
mediated signaling mechanism via this pathway have been well established.
In the case of Type I IFNs, the receptor is composed of two subunits, IFN-aRl
and IFN-aR2 (120). IFN-aRl and IFN-aR2 are constitutively associated with tyrosine
kinase 2 (Tyk2) and Jakl, respectively. When a monomeric Type I IFN is bound (121),
the receptor chains undergo a structural rearrangement and their associated Jaks are
rapidly autophosphorylated (119). In a major pathway for Type I IFNs, activated receptor
complexes subsequently regulate the phosphorylation of STAT1 and STAT2.
Phosphorylated STAT1 and STAT2 dimerize and recruit a non-phosphorylated factor
IRF-9 to form a heterotrimer called ISG factor 3 (ISGF3) (122), which enters the nucleus
and binds to IFN-stimulated response elements (ISRE) to initiate the transcription of
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certain ISGs demonstrated in Figure 8 such as MxA, IRF3 and OAS1 that possess this
promoter (123).
Besides ISGF3, activated Type IIFN receptor is also responsible for the
activation and homo- or heterodimer formation of other STATs (114, 124). While ISGF3
is the only complex that binds ISRE, these activated STAT homodimers bind another
type of element known as IFN-y activated site (125) elements and thereby induce the
transcription of GAS-presenting ISGs (126, 127). It has been proposed that different
combination of STATs may be induced to target the transcription of specific genes with
distinct functions (75). Of the many genes that are induced, the gene of our interest
belongs to the distinct dynamin superfamily.
2.4 Overview of the dynamin superfamily
The dynamin superfamily comprises a class of guanine-nucleotide-binding (G)
proteins, or GTPases (hydrolases that catalyze the hydrolysis of guanosine triphosphate
(GTP) to guanosine diphosphate (GDP) and phosphate). These proteins possess essential
functions in cellular processes relying on membrane remodeling (128). In addition to
classical dynamins, an increasing number of dynamin-related proteins have been assigned
to this superfamily (Fig. 9), such as the Mx proteins (129), the GBP/atlastin family (730),
the bacterial dynamin-like proteins (BDLPs) (737) and the EHD ATPases (732). All
members share common biochemical properties and have (i) low binding affinity to GTP,
(ii) the propensity to self-assemble and oligomerize around lipid templates and (iii)
increased nucleotide hydrolysis rates promoted by oligomerization (733, 734).
Because of these features, the dynamin superfamily of large GTPases are
distinguished from the small Ras-like and other regulatory GTPases, such as the a-
23
subunits of heterotrimeric G-proteins and the translation factors in protein synthesis (128,
135-138). These distinct biochemical features of dynamin superfamily members can be
explained by their special multi-domain architecture. Apart from a large N-terminal
GTPase (G) domain containing around 300 amino acid residues, the members usually
also have two additional domains: the so-called middle domain (2) and the GTPase
effector domain (GED) that were thought be crucial to the oligomerization and GTPase
activity stimulation at least in some members, such as dynamins and Mx proteins (Fig. 10)
(139-142). Different members within the superfamily also carry other domains
individually for their specific cellular functions (Fig. 11) (128).
Primary sequence analysis indicates that the G domain of dynamin superfamily
members is an extended form of the canonical GTPase fold observed in Ras and many
other GTPases, as the four essential motifs, sequentially named G1-G4, are all present.
All these motifs contribute to the binding and hydrolysis of GTP, and they are hallmarked
by one or more conserved amino acid residues (143). The Gl motif has the consensus
sequence of GXXXXGKS/T ("X" stands for an unspecific residue) and form the
conserved phosphate-binding (144) loop, which is responsible for the interaction with the
P- and y-phosphate of the nucleotide (145). The G2 motif contains an invariant threonine
residue that binds the y-phosphate of GTP (135). The G3 motif has a DXXG composition
where the conserved aspartate binds a catalytic magnesium ion (Mg2+) and the glycine
coordinates y-phosphate (143). The G4 motif has a T/NKXD signature (except for GBPs
and OPAs) that is involved in the coordination of the nucleotide base and the ribose
(135). Two conserved loop regions in the G domain were named switch I and II, as they
undergo large conformational changes in the GDP- and GTP-bound form in analogy to
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the switch that mediates the "on" and "off state of the molecule (146). Switch I covers
the G2 motif and the switch II overlaps with the G3 motif.
In contrast to many molecular structures of the G domain, little structural
information ofthe much less conserved MD and GED of the main dynamin superfamily
members (such as dynamins, DLPs or Mx proteins) is known. According to secondary
structure prediction based on primary amino acid sequence, MD and GED fold
predominantly into a-helices (147), which was also observed for some far relatives of
dynamins and Mx proteins (130, 131).
2.4.1 Mx proteins
Mx proteins are key mediators of the IFN-induced innate antiviral response in
vertebrates (129). Their discovery dates back on genetic studies on inborn resistance of
mice to influenza viruses about 40 years ago (148, 149). Mxl protein was cloned from
influenza virus resistant mice (150) and was shown to mediate cell intrinsic antiviral
activity (151). The mouse Mxl is encoded by the Mxl gene on chromosome 16 and most
influenza virus-susceptible mouse strains carry large deletions or nonsense mutations in
this region (152).
Later it was found in the mouse genome that another gene, named Mx2, which is
closely linked with Mxl on chromosome 16, is also defective in inbred mouse strains
(153). Human Mx proteins were identified from cross-interactions of a monoclonal
antibody (2C12) against mouse Mxl in human cells (154). Subsequently, two proteins
named MxA and MxB were found to be encoded by closely linked genes on human
chromosome 21 (155-157). Subsequently, IFN-inducible Mx genes were identified in
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many vertebrates and their encoding proteins can be classified into several subgroups
based on sequence similarities (Fig. 11) {129).
Mx proteins have a molecular mass of around 75 kDa, and are composed of the
N-terminal G domain, the MD and the C-terminal GED as described in the dynamin
superfamily. The G domain ofMx proteins share 40% sequence identity to other dynamin
superfamily members whereas for MD and GED only 20% identity is observed (158).
Compared to dynamin, Mx proteins usually have an extra unstructured N-terminal stretch
of amino acids with unknown function, and this stretch varies in the length and sequence
of amino acid residues for Mx proteins from different species.
In solution, Mx proteins self-assemble into high-order oligomers in ring-like or
helical arrangement (159, 160). In living cells, rodent Mx proteins accumulate in distinct
nuclear dots near promyelocytic leukemia (PML) nuclear bodies (NBs) in IFN-treated
cells (161), while human MxA forms punctuate granula in the cytoplasm and partially co-
localizes with COPI positive membranes of the smooth ER-Golgi intermediate
compartment (162). It was concluded that these Mx assemblies may serve as an
intracellular storage form from where more Mx proteins can be recruited when needed
(163).
Mx proteins have different specificities in their antiviral spectrum and this may be
a result of their subcellular localizations to some extent. For example, rodent Mxl has a
C-terminal nuclear localization signal (NLS) and inhibits multiplication of
orthomyxoviruses, such as influenza virus (FLUAV) and Thogoto virus (THOV) which
replicate in the cell nucleus (129). In contrast, cytoplasmic rodent Mx2 confers resistance
to those viruses that replicate in the cytoplasm, such as rhabdoviruses (e.g. vesicular
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stomatitis virus, VSV) and bunyaviruses (e.g. LaCrosse virus, LACV) (163). On the other
hand, cytoplasmic human MxA is able to suppress a broad range of different virus
classes, including members of the bunyaviruses in Figure 12, orthomyxoviruses,
paramyxoviruses, rhabdoviruses, toga-viruses, picomaviruses, reoviruses and hepatitis B
virus (HBV), a DNA virus with a genomic RNA intermediate, despite their different
replication sites in the cell (129, 163).
Recently, it was reported that human MxA can also suppress a large dsDNA virus
named African swine fever virus (ASFV) (164); however, nucleus-localizing human
MxB has no apparent antiviral activities (165). As for avians, chicken Mx proteins also
lack the ability to fight against avian influenza viruses (166). In the case offish Mx
proteins, Atlantic salmon Mxl was reported to be able to inhibit the activity of an
influenza-like fish virus named infectious salmon anaemia virus (ISAV) and an aquatic
birnavirus called infectious pancreatic necrosis virus (IPNV) (167).
From early transgenic mouse and other cell-based assays, it was demonstrated that
both mouse and human Mx proteins possess intrinsic antiviral activity in vivo and are
able to function autonomously in the absence of other type I IFN-induced factors (129).
There have been increasing amounts of research carried out in order to elucidate their
antiviral mechanism. It has been suggested that Mx proteins associate with essential viral
components and thereby block their functions. For example, human MxA was shown to
interact with THOV and LACV NP in vitro in a co-sedimentation assay (168). This
interaction was also observed in a so-called mini replicon assay that mimics the in vivo
viral replication with a minimum viral genome. Based on these studies, it was suggested
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that MxA does not recognize unassembled viral components but rather assembled
nucleocapsids (169).
Further studies revealed that human MxA binds to the NP ofbunyaviruses and
forms MxA/NP copolymers residing in the smooth ER-Golgi intermediate compartment,
which would lead to a depletion ofNP at the replication sites of the virus (7 70). Based on
these results, it has been proposed that Mx proteins interfere with the intracellular
allocation of viral components by missorting them (129). However, as the relevant
structural information is lacking, the antiviral mechanism for Mx proteins on the
molecular level still remains unclear.
2.4.2 Myxovirus resistance A/Myxovirus resistance 1
Mx proteins are among the few effector proteins of the IFN a/(3 system with
known antiviral activity. They are highly conserved large GTPases with homology to
dynamin and have been found in all vertebrates species investigated so far, including
mammals, birds, and fish (158). These proteins present a highly conserved N-terminal
GTPase domain of ~300 amino acids, a central interactive domain of ~ 150 amino acids,
and a GTPase effector domain (GED) of ~ 100 amino acids which encompasses two
leucine zippers that have the capacity to form a-helices illustrated in Figure 13
The human MX1 gene encodes for the human MxA protein which is a
cytoplasmic protein that is rapidly induced in response to acute viral infections (171).
Human MxA is a 76-kDa protein that encompasses GTPase activity with a low affinity
for GTP and a high GTP turnover rate (/ 72, 173). As to the GTPase activity of purified
histidine-tagged human MxA (His-MxA), the GTP turnover was calculated to be 27 min-
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1, and the dissociation constant (Kd) of His-MxA to GDP and GTP were measured to be
100 uM and 20 uM, respectively (173).
These Mx proteins are abundantly expressed in interferon-treated cells and play a
crucial role in the early antiviral defense against certain RNA viruses which has been
demonstrated in studies with transgenic mice (174-176). Human MxA is shown to inhibit
multiplication of several RNA viruses in various families including ssRNA and dsRNA
such as influenza, vesicular stomatitis virus (VSV) (177), measles virus (178), Thogoto
virus (179), Bunyavirus (180), and Semliki forest virus (181). MxA has also been shown
to confer resistance to some DNA viral genomes. It recognizes the nucleoprotein of the
viral nucleocapsid and prevents viral replication by various mechanisms, depending on
the replication site. The proposed antiviral mechanism ofMxA is illustrated in Figure 14.
Studies with human MxA protein have shown that the GED is able to specifically
contact the middle domain, and that interaction is critical to constitute a functional
GTPase domain, as well as for oligomerization (182, 183). For MD and GED, a single
point mutation at Leu612 to lysine (L612K) ofhuman MxA resulted in a non-
oligomerizable form that is defective in GTP hydrolysis and rapidly degraded (182), but
still maintains some antiviral activity (140).
Another single point mutation, E645R in human MxA, was shown to have altered
specificity and mode of action against vesicular stomatitis virus (VSV) (184).
Furthermore, the region comprising residues 432-471 was shown to be the binding site of
antibody 2C12 (185), and residue 564 was found to be a proteinase K cleavage site (186).
Based on these experimental results and the knowledge gained from the GBP1 structure
(130), a hypothetical domain arrangement was proposed for MxA which contains a
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globular G domain with MD and GED folding into an anti-parallel helical bundle (163).
Human MxA was shown to bind to negatively charged membranes and form ring-like
oligomers that tubulate liposomes in a way similar to dynamin (757, 188).
MxA wraps around the nucleocapsid, hence preventing it from entering the
nucleus or translocating from the replication site (189), whereas in other cases it inhibits
RNA transcription (190). MxA also plays a role in the context of cancer. Although it is
induced by interferons, there is some evidence that nuclear factors also regulate it.
Prostate carcinoma cell lines were found to express MxA even without cytokine stimuli,
indicating a more complex regulation (191). MxA was also shown to prevent cell motility
by interacting with tubulin which requires it GTPase domain. Although it is not essential
for mitosis, it also affects membrane remodeling and endocytosis. In addition, several
cancer cell lines were demonstrated to express MxA even in the absence of viral
infection.
There is also evidence that MxA may play a role in the apoptotic pathway and
may be required for the induction of apoptosis. A significantly higher level of caspase-3
activity was detected in wild-type MxA transfected and treated esophageal cancer cells
compared to normal cells treated with 5-FU (192). There is evidence, that MxA could be
deleted on chromosome 21 due to the possible fusion ofTMPRSS2 and ERG which is
associated with aggressive, invasive prostate tumors (191). In addition, it was found, that
in breast cancer special AT-rich binding protein 1 (SATB1), a global regulator which
controls IFN-inducible genes, suppresses MxA (191) by chromatin remodeling (193).
Many of the targets of SATB1 are regulated in response to activated Wnt-pathway (194)
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which may explain how SATB1 activity promotes tumor growth and metastasis in breast
cancer (195).
In primary head and neck squamous cell carcinoma (HNSCC) the MxA gene is
hypermethylated (196). It has been reported that the hepatitis B virus (HBV), which leads
to liver cancer, core protein is able to directly inhibit transcription of MxA (197). Another
study has shown that despite that, MxA is able to inhibit HBV replication (198).
In general, MxA appears to interfere with steps involving viral transcription
although the exact mechanism of action is not known or fully understood, but MxA has
exhibited various other functions independent of antiviral activity. It could be possible
that MxA may have a role in prostate cancer initiation by interfering with viral infection
in pre-initiation stages of PCa. It is also possible that MxA could be performing an
entirely different function in prostate cancer. There is increasing evidence that Mx
proteins are involved in various other processes and according to Muller et al. increased
synthesis ofMx proteins maybe deleterious to the organism (199). This shows that Mx
proteins may have different functions in other species beside the antiviral defense;
therefore it is imperative to investigate this protein in prostate cancer.
CHAPTER 3
THE MYXOVIRUS RESISTANCE A (MxA) GENE -88 G>T SINGLE
NUCELOTIDE POLYMORPHISM IS ASSOCIATED WITH PROSTATE
CANCER
This chapter ofmy work is published in Infection, Genetics, and Evolution. 2013 Feb
22;16C:186-190.
3.1 ABSTRACT
Background: Myxovirus (influenza virus) resistance A (MxA) is an interferon
stimulated antiviral protein that is required for a complete antiviral response. MxA
polymorphism (rs2071430) is located within an Interferon Stimulated Response Element
(ISRE) at position -88 in the gene's promoter region, and it has been associated with
increased susceptibility to infections and various diseases. In general, the low promoter
activity genotype (GG) promotes susceptibility, whereas the high promoter activity
genotype (TT) confers protection to Hepatitis C viral infection. MxA's role in prostate
cancer is not fully understood. Previous studies have shown that MxA may be a mediator
of the effect of IFN on normal and tumor cell motility. MxA may act as a tumor
suppressor and the level of expression may be a predictor of metastatic potential. Based
on this information, in this study we investigated the association of this functional
polymorphism (rs2071430) in MxA with prostate cancer.
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Methods: Sample size and power was calculated using the PGA software. Genomic
DNA from controls (n=140) and prostate cancer patients (n=164) were used for
genotyping SNP rs2071430 on all samples. Statistical analysis was performed using
logistic regression model.
Results: A significant association was observed between rs2071430 genotype GG and
prostate cancer. Individuals harboring the GG genotype are at an increased risk of
prostate cancer. Data stratification reveals that the mutant GT genotype offers some
protection against prostate cancer in Caucasians.
Conclusions: MxA SNP rs2071430 GG genotype is significantly associated with prostate
cancer irrespective of race. However, data stratification also suggests that the GT
genotype is under-represented in Caucasian subjects suggesting its role in protection
against prostate cancer in Caucasians. Although MxA is primarily implicated in viral
infection, but it may be also be associated with prostate cancer. Recent studies have
implicated viral and bacterial infections with increased prostate cancer risk. Expression of
the high promoter activity genotype may offer resistance to prostate cancer infection and
possibly influence clinical outcomes.
3.2 INTRODUCTION
The human Myxovirus (influenza virus) resistance 1 gene encodes for the human
MxA protein (76Kda) a cytoplasmic protein that is rapidly induced in response to acute
viral infections (7 71). MxA belongs to the family ofMx proteins which are among the
few effector proteins of the IFN a/b system with known antiviral activity. The Mx
proteins are abundantly expressed in interferon-treated cells and play a crucial role in the
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early antiviral defense against certain RNA viruses which has been demonstrated in
studies with transgenic mice (774-176). Human MxA is shown to inhibit multiplication
of several ssRNA and dsRNA viruses including influenza, vesicular stomatitis virus
(VSV) (777), measles virus (178), Thogoto virus (179), Bunyavirus (180), and Semliki
forest virus (181). MxA has also been shown to confer resistance to some DNA viral
genomes (795) (164). In general, MxA appears to interfere with steps involving viral
transcription although the exact mechanism of action is not known or fully understood.
MxA is a highly conserved large GTPase with additional homology to the
dynamin super-family and have been found in all vertebrate species investigated so far,
including mammals, birds, and fish (755). These proteins present a highly conserved N-
terminal GTPase domain of ~300 amino acids, a central interactive domain of ~ 150
amino acids, and a GTPase effector domain (GED) of ~ 100 amino acids which
encompasses two leucine zippers that have the capacity to form a-helices. The MxA
GTPase domain has a low affinity for GTP but high GTP turnover rate which is
indicative of efficient cycling achieved only within dense protein complexes typically
assembled on the membrane surface (7 72, 173, 200). Studies with human MxA protein
have shown that the GED effector domain is able to specifically contact the middle
domain, and that this interaction is critical to constitute a functional GTPase domain, as
well as for oligomerization (134, 189) and antiviral functions (752, 753).
The MxA gene exhibits over 590 polymorphisms (NCBI dbSNP). It was
previously reported that a SNP at nucleotide position -88 (G or T) in the promoter region
of the gene modulates MxA function at multiple levels including expression. MxA
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mRNA is significantly up-regulated with the mutant "T" (TT or GT) allele as compared
to the wild type homozygous "G" allele (201-203).
This functional polymorphism (rs2071430) is well studied and demonstrates an
association with various diseases such as susceptibility to hepatitis C virus (204), SARS
(205), and sub-acute sclerosing panencephalitis (206). Interestingly, an interferon
stimulated response element (ISRE) is located around the single nucleotide
polymorphism (rs2071430) in the promoter region and can also influence MxA promoter
activity. The T allele restores and the G allele attenuates ISRE binding due to sequence
homology (204, 207). Functional promoter studies using MxA luciferase reporter assay
has also demonstrated that promoter activity is highest in individuals with TT genotype
and lowest in the GG genotype (203, 206).
The role of MxA in prostate cancer is not fully understood. A previous study
(191) implicated MxA as a potential metastasis suppressing gene in prostate cancer
suggesting that its expression could be a key indicator of metastatic potential. We
hypothesized that the functional polymorphism rs2071430 leading to attenuated MxA
expression could be a genetic risk factor for prostate cancer. Our results demonstrate that
rs2071430 polymorphism is associated with prostate cancer and that a specific rs2071430
genotype (GG) may confer an increased susceptibility to prostate cancer.
3.3 MATERIALS AND METHODS
3.3.1 Samples
The genotyping protocol and use ofhuman samples in the study were approved
by IRB at Clark Atlanta University. Genotyping was performed on a total of 304 samples.
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The numbers of cancer and normal samples were approximately 50% each of the total
sample set (Table I). Retrospectively collected buffy coat samples were obtained from
Bio-specimen Shared Resource, KU Cancer Center, University of Kansas Medical Centre
and Cooperative Human Tissue Network (CHTN, Southern Division) following
appropriate protocol review and approval. The purified genomic DNA samples were
obtained commercially from BioServe Inc. (Beltsville, MD). All samples were stored at -
80 until analysis. De-identified comprehensive clinical information regarding age,
ethnicity and stage was available for all samples. However, family history of prostate
cancer, PSA level and Gleason score was not available for all samples hence were not
included in final statistical analysis.
3.3.2 DNA isolation
Genomic DNA was isolated (and stored at -80C) from cultured cells or buffy coat
using AquaPure total genomic DNA isolation kit (Bio-Rad). On an average
approximately 30 jig ofDNA was routinely isolated from 300 ul of buffy coat.
3.3.3 Genomic PCR
Genomic PCR was carried out in a 25 ul PCR reaction that consisted of 12.5ul
GoTaq Colorless Master Mix (Promega), 30 ng genomic DNA and 400 pM of 5' and 3'
primer each. The PCR was carried out for 35 cycles with annealing temperatures 52.9C
for rs2071430. The following primers were used rs2071430: Forward 5'-TGT ATA CCT
GCA AGT CAC AGG, Reverse 5'-TGT TAG TTA CTA GCA GCC GAG, nested primer
for rs2071430: 5'-GAG CAC CTT GAT CCT CAG AC.
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3.3.4 SNP detection
The rs2071430 polymorphism was detected by sequencing the PCR amplicon
spanning the above stated SNP using the primer pairs indicated above. An aliquot of the
respective PCR reaction was first analyzed on 1.5% agarose gel to confirm specificity
and quality of the reaction in terms ofband size and absence of any background PCR
product. Once confirmed, the remaining PCR product was cleaned using ExoSAP-IT
(USB) before sequencing on the AB sequencer (DNA sequencing Lab, Morehouse
School of Medicine, Atlanta, GA). The sequencing was performed using a nested primer
within the rs2071430 PCR product. The sequences were scanned using ABI sequence
scanner and the SNPs were manually detected. The amplicons showing low quality reads
were re-sequenced. The single nucleotide polymorphisms were also detected by
SNPdetctor (208) to ensure that the SNPs were due to heterozygous allelic variations and
not due to sequencing artifacts.
3.3.5 Statistical analysis
Each of the polymorphisms was tested for association with prostate cancer. Odds
ratio and 95% confidence intervals were calculated for the genotype in association with
prostate cancer using logistic regression analysis with adjustment for age. Relationship
between genotype distribution with subjects stratified with race and age were also
analyzed using the above model. NPSS version 2007, version 07.1.19 and SigmaStat
v3.5 was used for statistical analysis. The sample size calculations and power were
calculated using the "Power for Genetic Association Analyses" (PGA) package in Matlab
(available on the National Cancer Institute website) (209) using following parameters:
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90% power, alpha=0.05, cancer prevalence of 250/100,000 men (actual for all races,
white and black is 156.9, 150.4 and 234.6 per 100,000 men respectively as per SEER),
minor and major allele frequencies shown in table III (excluding TT allele), case control
ratio of 1 and relative risk ofprostate cancer in African American men as 2.5 as
compared to Caucasians. Using these calculations the sample size was approximately
110 samples (±23). This sample size was achieved in this study.
3.4 RESULTS
3.4.1 Sample demographics
A case-control study was performed to investigate rs2071430 genotype on 304
samples collected retrospectively. The samples were distributed equally (p=0.73)
between cases (N= 164, 53.9%) and controls (N=140, 46.1%). The mean age of cancer
samples was 63.7 ± 0.746 years, and the mean age of normal samples was 60.2 ±1.3
years. Both these groups were considered age matched (p = 0.273) (Table I).
Comprehensive statistical analysis based on Chi2 analysis indicated the lack of any bias
in the incidence of prostate cancer among the racial and age groups (Caucasians (53.3%)
and African Americans sample sets (46.7%, Chi2=0.61).
3.4.2 MxA SNP rs2071430 in population
We first wanted to understand the population distribution of the rs2071430
genotype in the normal population published in NCBI dbSNP database. The results
showed that Caucasian and Hispanic subjects lack the homozygous TT genotype (Table
II). The TT genotype was observed at low frequency in African Americans (4.2%)
whereas in the subjects with Pacific Rim heritage, the TT genotype frequency was
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highest at 16.7%. These results clearly suggested a strong racial distribution of the minor
TT genotype (Table II). In the normal population, the GG genotype in NCBI database
was 70% in African American (n=24) but 50% in our dataset (n-60). A recent study
(210) showed that the MxA GG genotype distribution in African population (consisting
of subjects from Libya, Cameroun, Niger or Rwanda, none from African American
background) was 80%. The genotype distribution in our data set and those reported
elsewhere (e.g. Table II) could be due to sample size and ethnic background (210).
3.4.3 Sample set frequency of rs2071430 polymorphism
The frequency of rs2071430 genotype in our normal mixed race sample set
(58.6% (GG), 35.7% (GT) and 5.7% (TT)) was nearly consistent with those reported for
other heterogeneous control populations (NCBI dbSNP database, Table II, PI dataset:
72.5% (GG), 22.5% (GT) and 5% (TT). In our study, the rs2071430 allele frequency also
conformed to Hardy-Weinberg equilibrium in the African American population (chi-
square 2.23, df=2,/? =0.11). There was a marked deviation from Hardy-Weinberg
equilibrium in Caucasian sample set due to lack of TT genotype. The frequency
distribution ofrs2071430 in our complete sample set and samples stratified by race are
listed in Tables III and IV respectively.
3.4.5 rs2071430 distribution in the sample and its association with prostate cancer
Each one of the genotypes was tested for its association with prostate cancer for
all samples and in samples stratified by race. The combined cancer and control groups
revealed that GG was a major (dominant) genotype (65.8%), whereas TT was a minor
genotype (3.9%, Table III). The heterozygous genotype GT (frequency: 30.3%) was used
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as a reference to calculate the association of each genotype with prostate cancer. The
odds of having cancer with GG genotype was found to be 71% higher (CI=1.041 - 2.818)
than the odds with GT (reference) heterozygous genotype. On the other hand, the odds of
the homozygous TT genotype decreased the risk ofprostate cancer by 40% but was not
statistically significant (CI= 0.167-2.116). Alternatively, the GG genotype was over
represented in the cancer case group (72%) as compared to the control group (58.6%)
while the TT genotype was overrepresented in the control group (5.7%) compared with
the cancer group (2.4%, OR=0.6, Table III).
3.4.5 Association of rs2071430 with prostate cancer and race
Sample stratification demonstrated that rs2071430 genotype distribution is
associated with race. The MxA genotype frequencies in the Caucasian subpopulation
were: 72 %(GG), 27 %( GT) and 1.2 %(TT). The corresponding MxA genotype
frequencies for the African American subpopulation were: 58.6 %(GG), 34 %(GT) and
7.1% (TT). The genotype frequencies in both these racial sub-populations tested showed
statically significant difference (chi-square 14.3, p=0.0021). The results clearly
demonstrated that GG genotype is over-represented in the Caucasian population whereas
the heterozygous GT and homozygous TT genotype is over-represented in the African
American population. These observation prompted us investigate the association of each
genotype with cancer in African-American and Caucasian sub-populations. Although,
GG genotype was associated with prostate cancer overall and over-represented in
Caucasians as stated above, no significant race specific association was observed with
cancer (OR 1.37, CI 0.769 - 2.442).
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The distribution ofGT genotype (used as reference to calculate overall risk, Table
III) displayed strong association with African American as compared to Caucasians (OR
2.07, CI 0.897 - 4.780). The GT genotype was not associated with increased risk of
cancer in African American (cancer 28.2% vs. normal 24%). Surprisingly, the GT
genotype showed strong association with Normal Caucasians (30.4%) as compared to
cancer Caucasians (17.4%). The odds ratio of cancer incidence in the Caucasian group
with GT genotype was 3.1 (p=0.01) implying that the odds for cancer case is lower in
Caucasians with a GT genotype. Unlike the African American subset, the TT genotype
was absent in the Caucasian normal group but was observed in the cancer group in both
racial sub-groups (16.6%). However, based on low frequency, the TT genotype showed
no statistical significance in terms of its association with the disease and between racial
sub-groups. No significant association with stage, Gleason grade and MxA rs2071430
was observed (data not shown).
3.5 DISCUSSION
Together with other interferon inducible antiviral genes such as oligoadenylate
synthetase 1 (OAS1) and PKR, MxA (66) polymorphisms were also shown to be
associated with specific disease, for example, multiple sclerosis and viral infections such
as influenza and SARS. In mice, type IIFN is effective against influenza viruses only if
the IFN-induced resistance factor Mxl is present (63).
Our previous study also demonstrated a strong association of an OAS1
polymorphism with prostate cancer with racial disparities (64). The OAS1 and prostate
cancer association study prompted to ask the question whether polymorphisms in other
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classical IFN inducible antiviral genes such as MxA are also common risk factors in
prostate cancer. For this study we selected a single functional polymorphic marker at
position -88 (rs2071430) in the promoter ofMxA gene. In general the rs2071430 GG
genotype promotes disease susceptibility whereas TT genotype confers protection
against Hepatitis C and B virus infection (203). At the mechanistic level, the functional
rs2071430 GG, GT and TT genotype results in the lowest, intermediate and highest MxA
expression activity, respectively (202, 211). In in vitro luciferase based reporter assays
and in PBMC the allele TT/GT at -88 demonstrated higher reporter activity and MxA
expression in response to IFN-alpha than the GG allele suggesting a functional ISRE
around rs2071430 (202). Consistent with these observations, the rs2071430 genotype was
proposed to predict responsiveness to IFN-alpha therapy and susceptibility of Multiple
sclerosis and Hepatitis C and B (201, 212).
There is a general lack of studies associating MxA polymorphisms with cancer.
Our results suggest that the low activity, GG, genotype is a risk factor for prostate cancer
whereas higher activity genotype, TT, protects against prostate cancer in general. These
results are significant and suggest that low MxA expression due to GG genotype could be
associated with prostate cancer especially in context of a functional study which
demonstrated that MxA acts as tumor suppressor. MxA inhibits the motility and
invasiveness of prostate cancer cells suggesting that its attenuated expression may
promote aggressiveness of the disease (191). The GTPase activity ofMxA appeared
necessary and sufficient for blocking prostate cancer cell (PC3) invasiveness.
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The low incidence of rs2071430 homozygous TT genotype in the Caucasian population is
essentially consistent with population wide genotype distribution reported in NCBI
dbSNP database (Table IV). According to previous literature, with the proximity of 35
base pairs apart the -88G>T and the -123OA (rsl 7000900) SNPs have been assumed to
be in linkage disequilibrium (LD) although not perfectly (213). We also have genotyped
this particular SNP collectively with rs2071430 (data not shown) but did not observe
strong association with prostate cancer. These results further consolidate the association
of rs2071430 with prostate cancer.
Collectively, the association studies and data stratification presented in this study
suggests that rs2071430 is specifically associated with prostate cancer risk although the
association between the two ethnic populations showed atypical results. Our present
findings are clinically very useful for future studies to determine whether the -88OT
SNP may influence clinical outcome or is a genetic factor for increased risk or
aggressiveness ofprostate cancer. Furthermore, the association oftwo interferon
inducible antiviral genes OAS1 and MxA, as shown in this study strongly suggests the
possible viral etiology of prostate cancer. A larger study addressing the association
between rs2071430 polymorphism and MxA expression in the prostate would be required
to firmly establish whether MxA genotype is associated with altered MxA expression.
Alternatively, the MxA rs2071430 genotype could lead to increased risk ofprostate
cancer due to complex gene-gene and/or gene-environment, (such as increased
susceptibility to infections) interactions.
CHAPTER 4
FUNCTIONAL SIGNFICANCE OF MxA IN PROSTATE CANCER
4.1 ABSTRACT
Myxovirus (influenza virus) resistance A (MxA) is an interferon regulated protein
responsible for a specific antiviral state against viral infection that has been shown to be
up-regulated by androgens in normal prostate epithelial cells; however, there is no known
role for MxA in cancer. Recent studies have indicated that MxA has the ability to
modulate apoptosis and inhibit metastasis. We analyzed different expression databases
for clinical evidence to investigate the association between MxA expression and prostate
cancer. GEO database (Figure 15), Oncomine (Figure 16) clinical database, and Prostate
Cancer microarray study (Figure 17) searches showed that MxA expression was inversely
correlated with PCa. The aim of this study was to investigate the expression MxA in
human prostate cancer and its functional significance on the cancer phenotype in prostate
cancer. The expression ofMxA protein in cancerous prostatic tissues and normal tissues
was examined by IHC. DU145 cell line was used to determine the apoptotic function of
MxA in vitro. DU145 cells were stably transfected with pSM2C-MxA to knockdown
MxA expression. Cell viability was determined by MTT assay. Flow cytometry and
Annexin V analysis were performed to observe the apoptotic activity in DU145 cells
without MxA. Expression of apoptosis-related genes was assessed by western blot.
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Trans-well Migration and Soft Agar Colony Formation assays were used to determine
MxA's tumorigenic potential. The expression ofMxA protein was significantly
decreased in cancerous prostatic tissues compared to the normal tissues. DU145 cells
lacking MxA showed not only significant increase in proliferation compared with the
vector controls, but also decreased apoptotic activity. The loss ofMxA expression also
resulted in an increase in migration in the ability to form colonies; thereby illustrating its
anti-tumorigenic potential in prostate cancer.
4.2 INTRODUCTION
Mx proteins belong to a family of dynamin-like large GTPases. They play a
pivotal role in the type I interferon-mediated response against a broad range of viral
infections. Mx proteins are key mediators of the interferon -induced antiviral response in
vertebrates and hence of great biological interest and medical importance (214). Their
discovery dates back to early studies on genetically determined inborn resistance ofmice
to influenza viruses. The mouse Mxl protein was originally found in influenza virus-
resistant mice and was shown to have intrinsic antiviral activity.
The critical role ofmouse and human Mx proteins in mediating the antiviral
activity of IFNs against specific viruses became evident early on but other roles for these
proteins have not been extensively studied. Results show that ovine Mx is up-regulated
during early pregnancy (215), Mx proteins have vesicle trafficking abilities (187), and
these proteins may be involved in mitosis (216). These studies illustrate alternative roles
ofMx proteins outside of antiviral activity.
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Human MxA is a 76kDa cytoplasmic protein known to be strongly induced by
IFN and its expression is a preferred marker for IFN biological activity in vivo. Recent
literature has shown that MxA mimics the IFN effect on motility, suggesting that it might
be a critical molecular mediator of the IFN effect (191). Down-regulation of a number of
IFN target genes has been reported in several studies of global gene expression in
prostate cancer. Shou et al.(27 7) Nagano et al (218), and Schulz et al (219) showed that a
significant portion of the genes whose down-regulation was associated with prostate
cancer tumorigenesis or tumor progression were IFN-inducible genes, including MxA. It
is of interest to determine the functional significance ofMxA in prostate cancer
progression.
4.3 MATERIALS AND METHODS
4.3.1 Cell culture and reagents
Cell lines and cell culture: Human prostate cancer cell lines LNCaP, DU145, and
PC3 were obtained from American Type Culture Collection (ATCC, Rockville, MD).
LNCaP cells were cultured in RPMI-10% Fetal Bovine Serum (FBS) with antibiotics and
DU145 and PC3 cells were maintained in Hams F-12 media supplemented with 10% Calf
Serum with antibiotics. Cells were cultured at 37°C in a fully humidified atmosphere
containing 5% CO2. Universal Type I Interferon was obtained from R&D Systems and
used at a concentration of 300 Units/mL. A Jak Inhibitor 1 (Calbiochem) was used at
concentrations of 15 nM and 30 nM for 24 hours. Docetaxel (Enzo) was used at a
concentration of 1 (o,M/mL for 2, 4, and 24 hours.
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4.3.2 Transfections
MxA was stably silenced in DU145 cells using gene specific shRNA retroviral
vectors (Open Biosystems) in pSM2c vector. The cells transfected with non-silencing
shRNA (RHS1707) was used as control. MxA was transiently overexpressed in LNCaP
cells using A0257-MX1 (GeneCoepia). Transfections and selection of transfectants
(puromycin) were performed as suggested by the manufacturer. Successful gene
silencing/overexpression were confirmed by qRT-PCR and Western blot analysis.
4.3.3 RNA extraction
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) as described
previously [43]. The final RNA pellet was re-suspended in diethylpyrocarbonate
(DEPC)-treated H2O at a concentration of 1 mg/mL and stored at -80°C until analysis.
4.3.4 Reverse transcription and qPCR
Total RNA was isolated from all cells using a Total RNA Extraction Kit (Omega
BioTek). cDNA was generated from 4 ug of total RNA using the Superscript II cDNA
synthesis kit (Invitrogen). Quantitative PCR was conducted using GoTaq qPCR reagent
(Promega) and transcript levels of MxA, IFN a, IFNp, p21, p27, Cyclin Dl, GAPDH,
GADD45, MMP13 were measured on a Bio-Rad System. All qPCR data was normalized
to GAPDH expression. Sequences of all primers are shown in Appendix Table 1.
4.3.5 Protein extraction
Protein samples were quantitated using the Bio-Rad DC Protein Assay according
to the manufacturer's protocol. A standard curve was determined and sample absorbance
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read at 750 nm. Samples were concentrated to 30 ug/uL volume and then mixed 1:1 with
2X Sample Buffer.
4.3.6 Western blotting
Total cellular protein was prepared from cultured prostate cancer cell lines using
M-PER (Thermo Scientific). Total protein was separated on 4-20% SDS-polyacrylamide
gel (BioRad) and subsequently blotted onto a nitrocellulose membrane (BioRad). The
blotted nitrocellulose membrane was subjected to Western blot analysis using protein
specific MxA antibody (Proteintech Lab Group). After washing with lx PBS with 0.5%
Tween 20, the membranes were incubated with a secondary antibody against rabbit/
mouse IgG and the signal was visualized using the Super Signal West Dura Extended
Duration Substrate (Thermo Scientific) and blots visualized using the Fuji Film LAS-
3000 Imager.
4.3.7 Immunohistochemistry
Prostate cancer tissue microarrays (TMA) consisting of 8 normal and 40 cancer
cores were purchased from US BioMax (Rockville, MD). Tissue microarray slides were
de-paraffinized in xylene and re-hydrated using standard protocols. Antigens were
retrieved by autoclaving in 0.01 M sodium citrate buffer pH 6.0 at 121C/20 psi for 30
min. The slides were then blocked for peroxidase activity in 3% H2O2 (in PBST: PBS
with 0.05%Tween 20) for 10 min and then blocked in 10% goat serum (PBST with 1%
BSA) for 2 h at room temperature. The blocked sections were incubated overnight at 4°C
with primary antibody (1% BSA in PBST). The slides were then washed twice with
PBST for 5 min each, and then incubated with secondary antibody (1% BSA in PBST,
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1:1000, HRP- goat anti-mouse; Thermo Scientific, Rockford, IL) for 1 h. The slides were
washed with PBST for 5 min and stained with DAB for 2 min. Slides were then
counterstained in hematoxylin and mounted with Immuno-mount (Thermo Scientific),
examined and photo-micrographs taken using the Zeiss fluorescent microscope with an
AxoimCam version 4.5 imaging system.
4.3.8 MTT proliferation assay
DU145+NS and DU145-MxA cells were used as target cells for the detection of
any differences in the bioactivity in the absence ofMxA using CellTiter 96 Non-
Radioactive Cell Proliferation Assay (Promega). Cells were seeded (5 x 103 cells/well) in
96-well plates in recommended growth media. After allowing cells to attach overnight,
medium was again replaced and 15 ul Dye Solution added and incubated at 37 °C in the
dark for 4 h. Following 4 h incubation, solubilization/stop solution was added and
incubated for 1 h. Absorbance was read at 570 nm using a 96-well plate reader. Three
independent experiments were carried out with similar results.
4.3.9 Flow cytometric analysis of cell cycle and apoptosis
The LNCaP and DU145 transfected cells were cultured in 24 well plates to a sub-
confluent density. After culture, the cells were collected by trypsinization and washed
with phosphate buffered saline. The cells were then fixed with 70% ethanol and stored at
-20°C overnight. The following day, cells were washed twice with ice cold phosphate
buffered saline PBS/FCS (10%) followed by a final wash in 1 x PBS. The cells were then
finally resuspended 1 mL of PBS (lx) containing 50 ug/ml RNase A, 0.1% TritonX-100
and 1 mM EDTA and then incubated at 37°C for 30 minutes. Finally, 20 ug/mL of
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propidium iodide was added. Data acquisition and analysis were performed on an Accuri
CFlow flow cytometer (CCRTD, Clark Atlanta University, Atlanta, GA). The cell cycle
profiles were then analyzed using FLOWJO (for cell cycle analysis) and CFlow for
apoptosis. At least 50,000 cells in each sample were analyzed to obtain a measurable
signal. All measurements were performed using the same instrument settings.
4.3.10 Scratch wound assay
The migratory properties of DU145 transfected cells were measured using a
scratch wound assay. Cells were plated in 6-well plates (5 x 105 cells/well) in Ham's F-12
with 5 % FBS and cultured overnight. Wells were scratched down the middle with a 200
ul pipette tip. Culture media were replaced with Ham's F-12 containing 5 % FBS. Cells
were allowed to migrate across the scratch for 48 h. Images of the scratch area were
recorded at 0, 24 and 48 hours, respectively.
4.3.11 Migration assay
In vitro cell migration assay was performed using 24-well trans-well inserts (8
urn; ref. 26). Briefly, cells were washed once with F-12 and harvested from cell culture
dishes by EDTA-trypsin into 50 ml conical tubes. The cells were centrifuged at 500 x g
for 10 minutes at room temperature; pellets were re-suspended into media supplemented
with 0.2% bovine serum albumin at a cell density of 3 x 105 cells/ml. The outside of the
trans-well insert membrane was coated with 50 ul of rat tail collagen (50 ug/ml)
overnight at 4°C. The next day, aliquots of rat tail collagen (50 ul) were added into the
trans-well inserts to coat the inside of the membranes. The inserts were left to stand for
1.5 h at room temperature before being washed thoroughly with 3 mL of F-12. Aliquots
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of 100 ul cell suspension were loaded into trans-well inserts that were subsequently
placed into the 24-well plate. The trans-well insert-loaded plate was placed in a cell
culture incubator for 5 h. At the end of the incubation, trans-well inserts were removed
from the plate individually; the cells inside trans-well inserts were removed by cotton
swabs. The cleaned inserts were fixed in 300 uL of4% paraformaldehyde (pH 7.5) for
20 minutes at room temperature. Cells were stained using HEMA 3 staining kit (Fisher
Scientific, Inc.). Stained cells were counted in four non-overlapping low-power fields of
a light microscope, and the average number of cells reflected the cell migration status in
each trans-well insert. To avoid experimental bias, a systematic random sampling
technique was applied in the selection of representative fields, in which sample
preparation and handling was executed by different persons. Results were expressed as
migration index, which is defined as the average number of cells per field for test
substance / the average number of cells per field for the medium control. Each
experiment was repeated at least three times using a different cell preparation.
4.3.12 Colony formation in soft agar
Cells were incubated in the presence of 0.5|ig/mL Puromycin before reseeding in
soft agar at low density to ensure the selection of transfected cells. After trypsinization
and counting, the cells were resuspended in medium containing 0.3% agarose and 0.5 ml
containing 500 cells was added to each well of 6-well plates. The cells were incubated at
37°C in a humidified incubator with 5% CO2 in for 14-20 days and colonies were
counted in an inverted phase contrast microscope.
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4.4 RESULTS
4.4.1 Prostate cancer tissues express less MxA
We first analyzed the expression ofMxA by IHC staining in a collection of
prostate cancer and normal tissue microarray slides. As shown in Figure 18, the MxA
protein was virtually undetectable in the highest grade ofprostate cancer but highly
expressed in normal prostatic tissue. The cellular localization ofMxA was mostly
cytoplasmic with some perinuclear staining as indicated by the arrows. These results
indicated that MxA has lower expression in clinical prostate cancers, suggesting MxA as
a promising target for prostate cancer therapy. This prompted us to investigate the
expression pattern ofMxA in our prostate cancer cell lines.
4.4.2 Expression of MxA in prostate cancer cells
It is known that MxA is an interferon inducible protein so the expression of
interferon alpha and beta were examined in the prostate cancer cell lines to see if the level
of interferons present correlates to the expression ofMxA in the prostate cancer cell lines
(Figure 19). The expression ofMxA was variable in all cells as shown in Figure 20. The
normal prostate cell line RWPE1 exhibited the highest expression (data not shown) which
correlates well with our tissue microarray data.
4.4.3 Regulation of MxA
In addition to MxA being IFN inducible we wanted to investigate the alternative
mechanisms by which MxA is regulated. We are reporting for the first time that MxA is
also a serum regulated gene in prostate cancer cells. Cells cultured in calf serum exhibit
constitutive expression of MxA, while cells cultured in FBS have reduced expression of
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the gene as shown in Figure 21. In androgen sensitive LNCaP cells; androgens down-
regulate the basal expression ofMxA (Figure 22). In cells which constitutively express
MxA, they are sensitive to the interferon pathway as illustrated in Figure 23.
We also wanted to investigate the possible viral dependent mechanism of
regulation. We used the prostate cancer cell line 22Rvl. These cells illustrated no
expression of endogenous interferons but exhibited higher expression of MxA. It is also
known that 22Rvl does produce high titer of the XMRV virus. We assayed all cell lines
for XMRV as shown in Figure 24. 22Rvl cells were the only population to contain the
virus while all other prostate cancer cell lines were negative. These results confirm viral
dependent regulation of MxA.
4.4.4 MxA overexpression leads to cell cycle arrest
In this study we wanted to investigate the functional significance ofMxA in
prostate cancer cells. We attempted stable transfection ofMxA in LNCaP cells which
proved to be lethal. Consistent with previous literature, permanent high-level synthesis of
MxA is detrimental (199); however, transient over-expression ofMxA showed a
significant Gl cell cycle arrest as seen in Figure 25. The Gl checkpoint is where
eukaryotes typically arrest the cell cycle if environmental conditions make cell division
impossible. This arrest was apparent by a significant up-regulation of p21 and down-
regulation of Cyclin Dl (Figure 26).
4.4.5 Silencing of MxA increased proliferation of DU145 cells
Because of the complexities of overexpression of MxA, DU145 model system
was used to silence MxA because of its constitutive expression as illustrated in Figure 27.
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To explore the effect ofMxA silencing on cell growth, MTT assays were performed at
24,48, and 72 hours, respectively, after stable transfection. We wanted to analyze the
effects of silencing MxA on the growth rate of the cells. Results showed that there was
an increase in cell proliferation in MxA silenced DU145 cells as compared to the Non
specific control (Figure 28). To further explore the effect ofMxA knockdown, cell cycle
analysis was performed in Figure 29. These cells were rapidly progressing through the
cell cycle which supports our data of increased proliferation.
4.4.6 MxA is a tumor suppressor in prostate cancer
After seeing the effects of loss ofMxA on proliferation we also wanted to see
what other effects it may have on the cancer phenotype. A scratch wound assay showed
that knockdown of MxA caused the wound in DU145-MxA cells to heal faster than the
non-silenced control cells in Figure 30. These results were confirmed in a Trans-well
migration assay illustrated in Figure 31. Cells with constitutive MxA were less migratory
than the transfected cells. There was also an increase in MMP-13 in MxA knockdown
cells (Figure 32). Proteins of the matrix metalloproteinase (MMP) family are involved in
the breakdown of extracellular matrix in normal physiological processes as well as in
disease processes, such as metastasis. This may provide some evidence as to the
mechanism by which motility increases in these cells.
Our results show a strong evidence ofMxA as a tumor suppressor in prostate
cancer. To confirm our hypothesis we performed a soft agar colony formation assay in
Figure 33. Anchorage-independent growth is one of the hallmarks of cell transformation,
which is considered the most accurate and stringent in vitro assay for detecting malignant
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transformation of cells and/or mechanism that block transformation phenotype. The soft
agar assay is the closest in vitro assay to in vivo studies. The results in Figure 34
confirmed that cells with silenced MxA has greater colony forming units (CFU) which
illustrates an anti-tumorigenic role for MxA.
4.4.7 MxA sensitizes prostate cancer cells to chemotherapeutic drugs
DU145 control and DU145-MxA cells were exposed to the chemotherapeutic
drug Docetaxel (DTX) for a period of 24 hours and Annexin V staining was performed.
Cells with MxA were more sensitive to DTX induced apoptosis as shown in Figure 35.
This suggests a possible role ofMxA as a novel prostate cancer therapeutic target. To
further investigate this we subjected the cells to immunocytochemistry with DTX
treatment in DU145 cell that express MxA. MxA did co-localize with alpha-tubulin
before treatment with DTX and after treatment that localization was disrupted as depicted
in Figure 36. MxA had very diffuse cytoplasmic staining before treatment; however, after
treatment MxA was localized in punctate dots. This intriguing observation will be
investigated further but may provide some mechanism ofhow MxA sensitizes these cells
to chemotherapeutic agents.
4.5 DISCUSSION
Our studies have for the first time shown an anti-tumor role for MxA in prostate
cancer. This study began with the database analysis identifying MxA expression as
inversely correlated with prostate cancer, and the notion that MxA has alternative
functions as antiviral activity. As demonstrated here through prostate cancer tissue
microarray a significant difference was seen in MxA protein expression. There is an
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abundance ofMxA in normal tissue but continuously decreasing amounts ofMxA the
more malignant the cancer, consistent with current literature (219). The prostate cancer
cell lines demonstrated variable expression ofMxA but overall expression was low. The
overall low expression ofMxA in prostate cancer could possibly be due to the
polymorphism in MxA's proximal promoter region. Our previous study established an
association ofMxA with prostate cancer risk, specifically the genotype with low
promoter activity (220) which results in reduced expression of MxA.
In the prostate cancer cell line, LNCaP, the basal expression ofMxA is down-
regulated by androgens. This phenomenon was supported by the results that MxA is also
serum regulated. Cells that were cultured in fetal bovine serum (FBS) had no expression
ofMxA but cells cultured in calf serum (CS) exhibited constitutive expression ofMxA.
Previous work using immortalized human meibomian gland and conjunctival epithelial
cells, androgens down-regulate genes involved in processes such as the immune response
and JAK-STAT signaling cascade (221). The level of androgens present in FBS alone
seems to be sufficient to decrease expression ofMxA including treatment with exogenous
androgens. Cells with constitutive expression ofMxA are sensitive to the classical
interferon signaling pathway, but 22Rvl cells also illustrate viral-dependent regulation of
MxA. This area of viral dependent regulation ofMxA in prostate cancer needs to be
further investigated.
To elucidate the functional significance ofMxA in prostate cancer and its effect
on the cancer phenotype we first looked at ectopically expressing MxA in LNCaP cells.
Expression of exogenous MxA in LNCaP cells resulted in significant Gl cell cycle arrest.
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This was supported by a reduction in Cyclin Dl and an up-regulation ofp21. It is known
that degradation of Cyclin Dl is sufficient to cause a Gl cell cycle arrest (222, 223). We
believe this down-regulation of Cyclin Dl to result from MxA's up regulation ofp21. p21
can down-regulate Cyclin Dl in a p53 independent or dependent manner (224). We
believe this to be p53 dependent due high level synthesis ofMxA (199) resulting in a
possible increase in p53 and apoptosis, thus there was no generation of a stable MxA
expressing cell line.
Because of this we knocked down the expression ofMxA cDNA in the prostate
cancer cell line DU145 and compared this effect with that of a non-specific control
vector. Loss ofMxA resulted in a slight increase in proliferation. There was also an
increase in the G2 cell cycle of cells with knock-down MxA (22.7% vs 13.9%). G2
phase is a period of rapid cell growth and protein synthesis during which the cell prepares
for mitosis (225). These results are consistent with the increase in proliferation. Taken
together these results prompted us to investigate MxA's effect on cell motility in prostate
cancer. According to a report published by Mushinski et al., MxA inhibits motility
comparable to IFN (191). IFN inhibits normal cell motility (226). Their results suggest
that MxA may be a critical molecular mediator of the IFN effect. Our results corroborate
the current literature to show that loss ofMxA results in increased wound healing. The
trans-well migration assay quantitated the findings of the scratch wound assay. Because
the degradation of the extracellular matrix and the basement membrane by proteases,
such as matrix metalloproteinases (MMPs) is critical for migration and invasion of cancer
cells, we investigated the expression of several MMPs. The DU145-MxA cells also
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showed an increase in MMP13 expression. This may provide some mechanism by which
motility is increased in these cells as compared to the vector control. Increased expression
ofMMP13 (227) and MMP9 are known to increase migration and motility and decreases
in these two MMPs have been shown to inhibit migration and invasion in oral cancer
(228).
Anchorage-independent growth is one of the hallmarks of cell transformation and
uncontrolled cell growth. The soft agar colony formation assay is considered the most
accurate and stringent in vitro assay for detecting malignant transformation of cells by
measuring proliferation in a semisolid culture media. Our results demonstrate that
depletion ofMxA leads to increased soft agar colony formation. This set of results in
conjunction with increased proliferation and migration after reduction ofMxA suggests
an alternative function ofMxA as an inhibitor of tumorigenesis in prostate cancer.
Expression of functional tumor suppressor genes should inhibit or limit the ability of cells
to grow in an anchorage independent manner (229-231) .
Consistent with our results illustrating MxA as a possible tumor suppressor in
prostate cancer our next goal was to identify if MxA was able to sensitize prostate cancer
cells to chemotherapeutic drugs. This was achieved by the treatment of DU145
transfected cells with DTX. Cells with reduced levels ofMxA also exhibited fewer cells
undergoing apoptosis. The cells with constitutive expression ofMxA were more sensitive
to the chemotherapeutic agent and resulted in increased apoptosis. This provides more
compelling evidence for MxA's anti-tumorigenic potential. Previous studies have
demonstrated that MxA interacts with tubulin (191) and other subcellular components
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(232). Studies have associated microtubules in migration (233-235). The
chemotherapeutic drug DTX is a clinically well-established anti-mitotic chemotherapy
medication. The main mode of therapeutic action ofDTX is the suppression of
microtubule dynamic assembly and disassembly (236). Our data suggest that MxA may
be important in this process so we wanted to see the interaction ofMxA and alpha
tubulin. The results indicated that MxA and alpha tubulin co-localize but the interaction
is abrogated after treatment with DTX. This may provide some evidence of how MxA
sensitizes the cells to chemotherapeutic drugs as well as its tumor suppressive functions
because DTX may be causing MxA to localize and form punctate dots because of its role
in microtubule dynamics. This area will be investigated further to determine the overall
significance. The results of the present study are particularly novel and supportive to the
alternative functions ofMxA to include a role as a possible tumor suppressor in prostate
cancer. These results could also prove to be profound in clinical translation and advocate
a new strategy for novel therapeutics in prostate cancer progression.
CHAPTER 5
CONCLUSION
In summary, we have shown reduced MxA expression is correlated with prostate
cancer. The results presented in this study demonstrate that MxA has anti-tumor
properties. MxA plays an important role in normal prostate epithelial cells by inhibiting
proliferation and inducing apoptosis. The expression ofMxA is decreased in prostate
cancer tissue; although MxA is expressed variably in all prostate cancer cell lines at both
the transcript and protein (low) levels. The explanation behind why the expression of
MxA is decreased could be attributed to its promoter polymorphism rs2071430. This
polymorphism which is a key factor in expression ofMxA is also a significant risk factor
for prostate cancer. The wild type homozygous "GG" genotype results in low promoter
activity/low expression and increased prostate cancer risk. The mutant "TT" genotype is
associated with high promoter activity/higher expression which was consistent with our
data. This mutant genotype was increased in normal samples than the cancer samples.
MxA is the preferred marker of interferon activity and has mainly been implicated in
studies related to interferon functions. MxA has been shown to function by the classical
IFN pathway but we have shown this protein to be regulated by viral-dependent, XMRV,
and viral-independent pathways including serum factors and androgens. Overexpression
ofMxA causes a Gl cell cycle arrest possibly due to down-regulation of Cyclin Dl by a
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p53 dependent up-regulation ofp21. Successful stable knock-down ofMxA initiates
increased proliferation, increased cell cycling, increased migration through the up-
regulation of MMP13, and a decrease in apoptosis. MxA has been shown to sensitize
prostate cancer cells to chemotherapeutic drugs perhaps through a microtubule dependent
mechanism which needs further investigation. The most compelling evidence presented
through this study was the increased formation of colony forming units in cells with






Figure 1: The prostate is a gland found only in males. It is located in front ofthe rectum
and below the urinary bladder. The size ofthe prostate varies with age. In younger men,

















Figure 2: The stages ofprostate cancer. In stage I, prostate cancer is confined only in the
prostate gland area. In stage II, the prostate tumor has grown inside the prostate but
hasn't yet extended beyond it. Stage III prostate cancer has spread outside ofthe prostate
minimally. Prostate cancer in stage III may involve nearby tissues. In stage IV, the cancer
























Figure 3: Proliferative Inflammatory Atrophy (PIA) to Prostatic Intraepithelial Neoplasia
(PIN) and Prostate Cancer. PIA may represent an intermediate step between normal
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Figure 4: Viruses and associated cancer types. Several viruses have been implicated in


















Figure 5: Secretion of interferon in an paracrine fashion. The cell on the left is infected
with a virus that triggers signals that lead to the secretion of IFN-jS which will bind to the
interferon receptor expressed by nearby cells that are not infected by the virus, acting in a
paracrine fashion to induce the interferon response that helps these cells to resist
infection. As depicted in the lower halfofthe cell, secretion may also occur in an











Figure 6: Type I and III IFNs bind to distinct receptors, but activate the same
downstream signaling pathways, and induce a widely overlapping set ofgenes through
the activation ofIFN stimulated gene factor 3 (ISGF3) and STATl homodimers. IFNy,
the only type II IFN, activates STATl homodimers, but not ISGF3, and thereby induces































































































































































































































































































Figure 7: The three major Interferon type I-induced antiviral pathways. 2. '-5'
oligoadenylate synthetase (OAS) is involved in RNA degradation. The double stranded
RNA (dsRNA)-dependent protein kinase (PKR) is responsible for inhibition of
translation and the MxA protein pathway functions by inhibiting virus RNA synthesis




















Figure 8: There are numerous different type I IFNs in humans, and they all signal
through the same cell surface receptor consisting of two chains called IFNAR1 and
IFNAR2; yet they can have markedly distinct cellular activities. Once the ligand binds to
the IFNAR1/IFNAR2 receptor complex the intracellular Jak-STAT pathway is activated.
Jakl and Tyk2 are phosphorylated and STAT1 and STAT2 are phosphorylated and
heterodimerize. They then recruit ISGF3 which enters the nucleus and binds to the
interferon stimulated response element to initiate transcription of interferon stimulated
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Figure 9: Dynamin superfamily members and their cellular localizations in animals and
plants. The dynamin family is divided into classical dynamins and the dynamin-like
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Figure 10: Domain architecture ofthe dynamin superfamily members. A cartoon
comparison ofdomain organization between different family members as indicated:
classical dynamins, dynamin like protein (DLPs), Mx proteins, Optic atrophy proteins



































Figure 11: Phylogenetic tree ofMx proteins. According to sequence similarities,
currently known vertebrate Mx proteins can be classified into five subgroups: fish Mx
avian Mx, MxB-like, rodent Mx and MxA-like. as: Atlantic salmon; hh: Atlantic halibut;
du: duck; ch: chicken; hu: human; ca: canine; rat: rat; mu: murine; ov: ovine; bo: bovine;
po: pocine. Figure adopted from (242)
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Figure 12: MxA antiviral activity during La Crosse virus infection. MxA GTPase
interferes with the intracellular transport of essential viral components. Membrane-
associated MxA blocks the transport ofvirus nucleocapsid protein by sequestering the
viral protein into large perinuclear aggregates. A) MxA illustrated by the green dots
forms small dots in uninfected cells. B) After viral infection MxA redistributes together
with the viral nucleoproteins into perinuclear complexes. The cytoskeleton is stained red
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Figure 13: Hypothetical domain arrangement ofhuman MxA. The GTP-binding domain
(88) contains the tripartite GTP-binding element (red bars) and the "self-assembly
domain". The C-terminal effector domain contains the "central interactive domain" (CID;
orange) and a "leucine zipper" region (LZ; green), also called "GTPase effector domain"















Figure 14: Functional organization of the antiviral module containing hsMxA. Upper
left: hsMxA monomer corresponds to a molecular component of the antiviral module.
Upper right: an hsMxA oligomer model represents a submodule with a defined
subfunction in the antiviral module. Lower: the proposed antiviral module comprises
components needed for the induction and regulation ofhsMxA activity (e.g. Type I
IFNs). IFN a/p are induced by viral RNA produced during viral replication leading to
activation of a cascade of intracellular receptors and transcription factors that activate the
IFN promoters. The FLUAV NS1 protein is an example of a viral antagonistic protein
known to suppress IFN induction. Newly synthesized and secreted IFNs bind to IFNAR
and activate the expression of ISGs including hsMxA via activation ofJAK/TYK and
STAT transcription factors. Upon infection, cytoplasmic hsMxA might recognize the
incoming viral RNP structures and self-assemble into rings resulting in a stable complex
that blocks viral RNP function. Figure taken from (244).
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Table 2: Population Diversity and genotype ofnormal but ethnically diverse populations




























G/G G/T T/T G T
0.725 0.225 0.050 83.80% 16.20%
0.839 0.161 0.000 91.90% 8.10%
0.708 0.250 0.042 83.30% 16.70%
0.870 0.130 0.000 93.50% 6.50%
0.458 0.375 0.167 64.60% 35.40%
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Table 3: Association ofMxA rs2071430 with prostate cancer. Genotype distribution for
all samples, corresponding odds ratio, 95% confidence interval and p values are shown
(OR= odds ratio, CI= confidence interval, N= number of samples and %= percent













































Total 304 100.0 164 100.0 140 100.0
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Table 4: Association ofMxA rs2071430 with prostate cancer among race. Genotype
distribution for Caucasian samples and African-American samples and corresponding
odds ratio and 95% confidence interval are shown (OR= odds ratio, CI= confidence








Race Cancer % Normal % OR 95% 95% CI
CI Upper
Lower
African 52 26 30 15 1.37 0.769 2.442
American











16 17.4 28 30.4













Figure 15: Meta-analysis ofMxA Expression in Metastatic Prostate cancer. GEO
Profiles ID: 34859781 Expression profiling by array, count, 171 samples. Expression of
MxA is decreased in metastatic prostate cancer [ red rectangle] as compared to normal


























Box Plot - Description
FIGURE 16: Oncomine database meta-analysis illustrates decreased expression ofMxA
















FIGURE 17: Box plot comparison of expression of selected genes in prostate cancer vs.
benign tissues by real-time quantitative RT-PCR. A: HPN; B: H0XB13; C: BCCIP; D:
GADD45A; E: MxA; F; TLR3; G: EPB41L3; H: EPB41L4B; I: FBLN1. Expression
values were determined for each sample in duplicate with < 10% variation. They are
indicated relative to the reference gene TBP determined in the same fashion. T: cancer
samples (n = 47), N: benign tissue samples (n = 13); p-values according to Mann-
Whitney tests. Figure used from (219). MxA is significantly decreased in prostate cancer









FIGURE 18: Immunohistochemistry (20X) ofMxA expression in a BioMax prostate
tissue microarray. Expression ofMxA high in normal tissue; however, as the grade of








FIGURE 19: RT-PCR of Interferon levels in prostate cancer cells. All prostate cancer
cells do not produce their own endogenous interferons with the exception of DU145 and
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FIGURE 20: Expression ofMxA in our well established prostate cancer cell lines by A)
PCR and B) Western blot analysis. There is variable expression ofMxA in the cell lines
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FIGURE 21: MxA is Serum Regulated. Western blot analysis illustrates MxA
expression in prostate cancer cell lines cultured in different serum. Cells cultured in fetal
bovine serum (FBS) resulted in decreased expression of MxA. Calf serum (CS) produces



















Figure 22: Regulation of MxA by Androgens. A) qPCR analysis ofMxA expression
after 12hr and 24hr DHT treatment respectively. Androgens down-regulate the basal
expression level of MxA. B) qPCR illustrates culturing the cells in serum devoid of
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Effects of 300U of IFNa and 15nM Jak Inhibitor on MxA expression in
DU145 cells
Figure 23: Interferon Regulation of MxA. RT-PCR illustrates cells with constitutive
MxA expression (DU145) are sensitive to the classical interferon signaling pathway.
Treating the cells with an inhibitor of this pathway results in loss of expression but
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Figure 24: Viral regulation of MxA. RT-PCR ofprostate cancer cell lines for detection
ofXMRV virus production. All cells were negative for XMRV virus with the exception
of 22Rvl cells which are known to produce high titer of the virus. 22Rvl also have high
expression ofMxA and do not produce their own interferons; thereby, illustrating viral
dependent regulation of MxA. Rl: First round of nested PCR, G: GAPDH, R2: Second




































Figure 25: Over-expression ofMxA in LNCaP cells. A) qRT-PCR analysis shows
successful transient over-expression ofMxA in LNCaP cell. B) The over-expression of
MxA in LNCaP cells had a profound effect on the cell cycle. There is a Gi cell cycle
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Figure 26: Effects of Gain of MxA expression on cell cycle. A) qRT-PCR illustrates a
decrease in Cyclin Dl expression in cells constitutively expressing MxA. B) p21 was up-
regulated in LNCaP+MxA cells as compared to vector controls. The down-regulation of
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Figure 27: Stable knockdown of MxA in DU145 prostate cancer cells. DU145 cells
were stably transfected and subjected to antibiotic selection. Cells were subjected to qRT-























Figure 28: Effect of Loss ofMxA on Proliferation. A)MTT proliferation assay illustrates
a slight increase in proliferation when MxA is stably knocked down. B) Expression of



















Figure 29: Cell Cycle Analysis ofDU145-MxA. A)Flow cytometry revealed an increase
in G2 of the cell cycle in cells with decreased MxA as compared to the Non-Specific
vector control. B) Expression of the CDKI p21 is decreased in DU145-MxA cells. This















Figure 30: Scratch Wound Assay. DU145+NS and DU145-MxA cells were plated in
6-well cell culture plates and a wound was created using a 20uL pipette tip. The cells
were allowed to heal over a period of 48 hours with pictures ofrandom fields taken at 0,
24, and 48 hours respectively. Cells with decreased MxA were able to heal the wound at








































Figure 32: Trans-well migration assay and MMP analysis. A) Quantitation ofmigration
index. DU145-MxA exhibited an increased migratory index as compared to cell with
constitutive MxA expression. B) Cells expressing constitutive MxA (DU145+NS) have







Figure 33: Soft Agar Assay Images. Microscopic images ofDU145+NS and DU145-











Figure 34: Quantitation ofAnchorage Independent Cell Growth. DU145-MxA cells had
greater colony forming units as compared to the vector control cell. These results
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DU145+NS 58.5 37.5 3.7
DU145-MxA 76.6 18.8 4.2
Figure 35: Annexin V Apoptosis Assay. DU145 transfected cells were treated with luM
DTX for 24 hours. Annexin V staining was done and the results were analyzed using
FACS analysis. Cells with constitutive MxA have increased apoptotic cells as compared
to silenced MxA cells. The reduction of apoptosis in DU145-MxA cells provides













Figure 36: Immunocytochemistry ofDTX treatment in DU145 cells that express MxA.
Left panel: No DTX treatment. Right panel: 2hr DTX treatment. MxA did co-localize
with alpha-Tubulin before treatment with DTX and after treatment that localization was
disrupted. MxA had very diffuse cytoplasmic staining before treatment (left); however,
after treatment MxA was localized in punctate dots (right). This intriguing observation
will be investigated further but may provide some mechanism ofhow MxA sensitizes
these cells to chemotherapeutic agents.
REFERENCES
1. American Cancer Society, I. (2013) What are the key statistics about prostate cancer?,
www.cancer.org.
2. Zatzkin, J. B. M., FACP. (2011) Stages of Prostate Cancer, WebMD, LLC.
3. Lilja, H. (2003) Biology of prostate-specific antigen, Urology 62, 27-33.
4. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H.
L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., and
Coltman, C. A., Jr. (2004) Prevalence of prostate cancer among men with a prostate-
specific antigen level < or =4.0 ng per milliliter, The New Englandjournal ofmedicine
350, 2239-2246.
5. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan,
R. C, deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., and et al. (1994)
Comparison of digital rectal examination and serum prostate specific antigen in the early
detection of prostate cancer: results of a multicenter clinical trial of 6,630 men, J Urol
151, 1283-1290.
6. Gomella, L. G., Liu, X. S., Trabulsi, E. J., Kelly, W. K., Myers, R., Showalter, T.,
Dicker, A., and Wender, R. (2011) Screening for prostate cancer: the current evidence
and guidelines controversy, Can J Urol 18, 5875-5883.
7. Crawford, E. D., Schutz, M. J., Clejan, S., Drago, J., Resnick, M. I., Chodak, G. W.,
Gomella, L. G., Austenfeld, M, Stone, N. N., Miles, B. J., and et al. (1992) The effect of
digital rectal examination on prostate-specific antigen levels, JAMA : thejournal ofthe
American Medical Association 267, 2227-2228.
8. Kuriyama, M., Wang, M. C, Papsidero, L. D., Killian, C. S., Shimano, T., Valenzuela,
L., Nishiura, T., Murphy, G. P., and Chu, T. M. (1980) Quantitation of prostate-specific
antigen in serum by a sensitive enzyme immunoassay, Cancer Res 40, 4658-4662.
9. Gomella, L. G. (2011) Celebrating the death ofPSA screening?, Can J Urol 18, 5987.
10. Sugar, L. M. (2006) Inflammation and prostate cancer, Can J Urol 13 Suppl 1,46-47.
11. Roberts, R. O., Bergstralh, E. J., Bass, S. E., Lieber, M. M., and Jacobsen, S. J. (2004)
Prostatitis as a risk factor for prostate cancer, Epidemiology 15, 93-99.
116
117
12. Dennis, L. K., Lynch, C. F., and Torner, J. C. (2002) Epidemiologic association between
prostatitis and prostate cancer, Urology 60, 78-83.
13. Morgantig, G. C, Arrigonig, Lovatig. (1956) Clinco-statistical and genetic research on
neoplasms of the prostate, Ada Genetica et Statistica Medica 6, 304-305.
14. Bruner DW, M. D., Parlanti A, Dorgan J, Engstrom P. (2003) Relative risk of prostate
cancer for men with affected relatives: systematic review and meta-analysis, Int J Cancer
107, 797-803.
15. Lichtenstein P, H. N., Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E,
Skytthe A, Hemminki K. (2000) Environmental and heritable factors in the causation of
cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland, N. Engl. J.
Med 343,78-85.
16. Carpten J, N. N., Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T,, Ewing C, G.
E., Hu P, Bujnovszky P, Makalowska I, Baffoe-, Bonnie A, F. D., Smith J, Stephan D,
Wiley K, Brownstein M, Gildea, D, K. B., Jenkins R, Hostetter G, Matikainen M,
Schleutker J,, Klinger K, C. T., Xiang Y, Wang Z, De Marzo A, Papadopoulos, N, K. O.,
Burk R, Meyers D, Gronberg H, Meltzer P,, and Silverman R, B.-W. J., Walsh P, Isaacs
W, Trent J. (2002) Germline mutations in the ribonuclease L gene in families showing
linkage with HPC1, Nat Genet 30, 181-184.
17. Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., Camp, N.
J., Carillo, A. R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J. M.,
Frank, D., Frye, C, Ghaffari, S., Gupte, J. S., Hu, R., Iliev, D., Janecki, T., Kort, E. N.,
Laity, K. E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B.,
Peterson, K. T., Reid, J. E., Richards, S., Schroeder, M., Smith, R., Snyder, S. C,
Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A. M., Labrie, F.,
Skolnick, M. H., Neuhausen, S., Rommens, J., and Cannon-Albright, L. A. (2001) A
candidate prostate cancer susceptibility gene at chromosome 17p, Nat Genet 27,172-180.
18. Xu, J., Zheng, S. L., Komiya, A., Mychaleckyj, J. C, Isaacs, S. D., Hu, J. J., Sterling, D.,
Lange, E. M., Hawkins, G. A., Turner, A., Ewing, C. M., Faith, D. A., Johnson, J. R.,
Suzuki, H., Bujnovszky, P., Wiley, K. E., DeMarzo, A. M., Bova, G. S., Chang, B., Hall,
M. C, McCullough, D. L., Partin, A. W., Kassabian, V. S., Carpten, J. D., Bailey-Wilson,
J. E., Trent, J. M., Ohar, J., Bleecker, E. R., Walsh, P. C, Isaacs, W. B., and Meyers, D.
A. (2002) Germline mutations and sequence variants of the macrophage scavenger
receptor 1 gene are associated with prostate cancer risk, Nat Genet 32, 321-325.
19. Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A.,
Malathi, K., Magi-Galluzzi, C, Tubbs, R. R., Ganem, D., Silverman, R. H., and DeRisi,
J. L. (2006) Identification of a novel Gammaretrovirus in prostate tumors ofpatients
homozygous for R462Q RNASEL variant, PLoSPathog 2, e25.
118
20. Silverman, R. H. (2003) Implications for RNase L in prostate cancer biology,
Biochemistry 42, 1805-1812.
21. Hassel BA, Z. A., Sotomayor C, Mara A, Silverman RH. (1993) A dominant negative
mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of
interferon, EMBOJ12, 3297-3304.
22. Smith JR, F. D., Carpten JD, Gronberg H, Xu J, Issacs SD, Brownstein MJ, Bova GS,
Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi
OP, Waker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS,
Trent JM, Issacs WB. (1996) Major susceptibility locus for prostate cancer on
chromosome 1 suggested by a genome-wide search, Science 274, 1371-1374.
23. Rennert H, B. D., Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov, S, S. L.,
Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y,, and A, O.-U. (2002) A novel
founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer
in Ashkenazi Jews, Am JHum Genet 71, 981-984.
24. Wang L, M. S., Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM,
Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN ((2002)
Analysis of the RNASEL gene in familial and sporadic prostate cancer, Am JHum Genet
77,116-123.
25. Kotar K, H. N., Thiffault I, Foulkes WD. (2003) The RNASEL 471delAAAG allele and
prostate cancer in Ashkenazi Jewish men, JMed Genet 40, e22.
26. Wiklund F, J. B., Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, Adami HO,
Augustsson-Balter K, Gronberg H. (2004) Genetic analysis of the RNASEL gene in
hereditary, familial, and sporadic prostate cancer, Clinical Cancer Research 10, 7150-
7156.
27. Palapattu GS, S. S., Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. (2004)
Prostate carcinogenesis and inflammation: emerging insights, Carcinogenesis.
28. Hsing, A. W., Reichardt, J. K., and Stanczyk, F. Z. (2002) Hormones and prostate cancer:
current perspectives and future directions, Prostate 52, 213-235.
29. Ritchey, J. D., Huang, W. Y., Chokkalingam, A. P., Gao, Y. T., Deng, J., Levine, P.,
Stanczyk, F. Z., and Hsing, A. W. (2005) Genetic variants of DNA repair genes and
prostate cancer: a population-based study, Cancer epidemiology, biomarkers &
prevention : a publication ofthe American Associationfor Cancer Research,
cosponsored by the American Society ofPreventive Oncology 14, 1703-1709.
30. Berwick, M., and Vineis, P. (2000) Markers ofDNA repair and susceptibility to cancer in
humans: an epidemiologic review, Journal ofthe National Cancer Institute 92, 874-897.
119
31. Angele, S., Falconer, A., Edwards, S. M, Dork, T., Bremer, M., Moullan, N., Chapot, B.,
Muir, K., Houlston, R., Norman, A. R., Bullock, S., Hope, Q., Meitz, J., Dearnaley, D.,
Dowe, A., Southgate, C, Ardern-Jones, A., Easton, D. F., Eeles, R. A., and Hall, J.
(2004) ATM polymorphisms as risk factors for prostate cancer development, British
journal ofcancer 91, 783-787.
32. Ross, R. K., Pike, M. C, Coetzee, G. A., Reichardt, J. K., Yu, M. C, Feigelson, H.,
Stanczyk, F. Z., Kolonel, L. N., and Henderson, B. E. (1998) Androgen metabolism and
prostate cancer: establishing a model of genetic susceptibility, Cancer Res 58,4497-
4504.
33. Panguluri, R. C, Long, L. O., Chen, W., Wang, S., Coulibaly, A., Ukoli, F., Jackson, A.,
Weinrich, S., Ahaghotu, C, Isaacs, W., and Kittles, R. A. (2004) COX-2 gene promoter
haplotypes and prostate cancer risk, Carcinogenesis 25, 961-966.
34. Li, Z., Habuchi, T., Tsuchiya, N., Mitsumori, K., Wang, L., Ohyama, C, Sato, K.,
Kamoto, T., Ogawa, O., and Kato, T. (2004) Increased risk ofprostate cancer and benign
prostatic hyperplasia associated with transforming growth factor-beta 1 gene
polymorphism at codonlO, Carcinogenesis 25, 237-240.
35. Ewart-Toland, A., Chan, J. M., Yuan, J., Balmain, A., and Ma, J. (2004) A gain of
function TGFBl polymorphism may be associated with late stage prostate cancer, Cancer
epidemiology, biomarkers & prevention : a publication ofthe American Associationfor
Cancer Research, cosponsored by the American Society ofPreventive Oncology 13, 759-
764.
36. Kuper H, A. H., Trichopoulos D. (2000) Infections as a major preventable cause of
human cancer, J Intern Med 248,171-183.
37. Coussens LM, W. Z. (2002) Inflammation and cancer, Nature 420, 860-867.
38. Shacter E, W. S. (2002) Chronic inflammation and cancer, Oncology 16, 217-226.
39. Lucia MS, T. K. (2004) Inflammation as a target for prostate cancer chemoprevention:
pathological and laboratory rationale, J Urol 171, S30-34.
40. De Marzo AM, M. V., Epstein JI, Nelson WG. (1999) Proliferative inflammatory atrophy
ofthe prostate: implications for prostatic carcinogenesis, Am JPathol 155,1985-1992.
41. Platz EA, D. M. A. (2004) Epidemiology of inflammation and prostate cancer, J Urol
171, S36-S40.
42. Feneley MR, Y. M., Chinyama C, Kirby RS, Parkinson MC ((1996) Ki-67 expression in
early prostate cancer and associated pathological lesions, J Clin Pathol 49, 741-748.
120
43. Putzi MJ, D. M. A. (2000) Morphologic transitions between proliferative inflammatory
atrophy and high-grade prostatic intraepithelial neoplasia, Urology 56, 828-832.
44. Shah R, M. N., Amin A, Macoska JA, Rubin MA. (2001) Postatrophic hyperplasia of the
prostate gland: neoplastic precursor or innocent bystander?, Am JPathol 158, \161-\112>.
45. Tsujimoto Y, T. H., Nonomura N, Okuyama A, Aozasa K. (2002) Postatrophic
hyperplasia of the prostate in Japan: histologic and immunohistochemical features and
p53 gene mutation analysis, Prostate 52, 279-287.
46. De Marzo AM, M. A., Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG.
(2003) Human prostate cancer precursors and pathobiology, Urology 62.
47. Habermacher GM, C. J., Schaeffer AJ. (2005) Prostatitis/Chronic Pelvic Pain Syndrome,
Annu Rev Med.
48. Roberts RO, L. M., Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. (1998) Prevalence
of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary
Symptoms and Health Status Among Men, Urology 51, 578-584.
49. van Leenders GJ, G. W., Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo
AM. (2003) Intermediate cells in human prostate epithelium are enriched in proliferative
inflammatory atrophy, Am JPathol 162, 1529-1537.
50. Dennis LK, L. C, Torner JC. (2002b) Epidemiologic association between prostatitis and
prostate cancer, Urology 60, 78-83.
51. Tan JK, P. D., Liew LC, Li MK, Wong ML. (2002) Prevalence of prostatitis-like
symptoms in Singapore: a population-based study, Singapore Med J 43, 189-193.
52. Nelson WG, D. M. A., Isaacs WB. (2003) Prostate Cancer, N. Engl. J. Med 349, 366-381.
53. Pagano, J. S., Blaser, M., Buendia, M. A., Damania, B., Khalili, K., Raab-Traub, N., and
Roizman, B. (2004) Infectious agents and cancer: criteria for a causal relation, Semin
Cancer Biol 74,453-471.
54. DiGiuseppe, J. A., Wu, T. C, Zehnbauer, B. A., McDowell, P. R., Barletta, J. M.,
Ambinder, R. F., and Mann, R. B. (1995) Epstein-Bar virus and progression of non-
Hodgkin's lymphoma to Ki-1-positive, anaplastic large cell phenotype, ModPathol 8,
553-559.
55. Yoshida, M. Molecular approach to human leukemia: isolation and characterization of
the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell
leukemia, Proc Jpn Acad Ser B Phys Biol Sci 86, 117-13 0.
121
56. Delviks-Frankenberry, K., Cingoz, O., Coffin, J. M., and Pathak, V. K. (2012)
Recombinant origin, contamination, and de-discovery ofXMRV, Current opinion in
virology 2, 499-507.
57. Schlaberg, R., Choe, D. J., Brown, K. R., Thaker, H. M, and Singh, I. R. (2009) XMRV
is present in malignant prostatic epithelium and is associated with prostate cancer,
especially high-grade tumors, Proc Natl Acad Sci USA 106, 16351-16356.
58. Hue, S., Gray, E. R., Gall, A., Katzourakis, A., Tan, C. P., Houldcroft, C. J., McLaren, S.,
Pillay, D., Futreal, A., Garson, J. A., Pybus, O. G., Kellam, P., and Towers, G. J. (2010)
Disease-associated XMRV sequences are consistent with laboratory contamination,
Retrovirology 7, 111.
59. Janeway, C. A. J., P. Travers, et al (2005) Immunobiology: The immune system in Health
and Disease, Garland Science, London & New York.
60. Sheehy, A. M., N. C. Gaddis, et al. (2002) Isolation of a human gene that inhibits HIV-1
infection and is suppressed by the viral Vifprotein, Nature 418, 646-650.
61. Bieniasz, P. D. (2004) Intrinsic immunity: a front-line defense against viral attack, Nat
Immuno5, 1109-1115.
62. Rand, U., Rinas, M., Schwerk, J., Nohren, G., Linnes, M., Kroger, A., Flossdorf, M.,
Kaly-Kullai, K., Hauser, H., Hofer, T., and Koster, M. (2012) Multi-layered stochasticity
and paracrine signal propagation shape the type-I interferon response, Molecular systems
biology 8, 584.
63. O'Gorman, W. E., et al. (2010) Alternate mechanisms of initial pattern recognition drive
differential immune responses to related poxviruses, Cell Host Microbe, 174-185.
64. Perry, S. T., M.D. Buck, S. M. Lada, C. Schindler, and S. Shresta. (2011) STAT2
mediates innate immunity to dengue virus in the absence of STAT1 via the type I
interferon receptor, PLoS Pathog.
65. Durbin, J. E., R. Hackenmiller, M.C. Simon, and D.E. Levy. (1996) Targeted disruption
of the mouse Statl gene results in compromised innate immunity to viral disease, Cell 84,
443-450.
66. Hahm, B., M.J. Trifilo, E.I. Zungia, and M.B. Oldstone. (2005) Viruses evade the
immune system thorugh type I inteferon-mediated STAT2-dependent, but STAT1-
independent, signaling, Immunity 22, 247-257.
67. Schindler, C, and Darnell, J. E., Jr. (1995) Transcriptional responses to polypeptide
ligands: the JAK-STAT pathway, Annu Rev Biochem 64, 621-651.
122
68. Sen, G. C, and Ransohoff, R. M. (1993) Interferon-induced antiviral actions and their
regulation, Adv Virus Res 42, 57-102.
69. Staeheli, P. (1990) Interferon-induced proteins and the antiviral state, Adv Virus Res 38,
147-200.
70. Critchley-Thorne, R. J., Yan, N., Nacu, S., Weber, J., Holmes, S. P., and Lee, P. P.
(2007) Down-regulation of the interferon signaling pathway in T lymphocytes from
patients with metastatic melanoma, PLoSMed 4, el 76.
71. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S.,
Pardoll, D., and Levitsky, H. (1998) Induction of antigen-specific T cell anergy: An early
event in the course of tumor progression, Proc Natl Acad Sci USA 95, 1178-1183.
72. Center, S. U. M. (2009) May 19,2009 ed., ScienceDaily.
73. Isaacs, A. a. J. L. (1957) Virus interference. I. The interferon, Proc R Soc Lond B Biol Sci
147, 258-267.
74. Pestka, S., C. D. Krause, et al. (2004) Interferons, interferon-like cytokines, and their
receptors, Immunol Rev 202, 8-32.
75. Platanias, L. C. (2005) Mechanisms of type-1- and type-II-interferon-mediated signaling,
Nat Rev Immunol 5, 375-386.
76. Pestka, S., J. A. Langer, et al. (1987) Interferons and their actions, Annu Rev Biochem 56,
727-777.
77. Pestka, S. (1997) The human interferon-alpha species and hybrid proteins, Semin Oncol
24, S9-4-S9-17.
78. LaFleur, D. W., Nardelli, B., Tsareva, T., Mather, D., Feng, P., Semenuk, M., Taylor, K.,
Buergin, M., Chinchilla, D., Roshke, V., Chen, G., Ruben, S. M., Pitha, P. M., Coleman,
T. A., and Moore, P. A. (2001) Interferon-kappa, a novel type I interferon expressed in
human keratinocytes, JBiol Chem 276, 39765-39771.
79. Conklin, D. C, F. J. Grant, et al. (2002) Interferon-e.
80. Buontempo, P. J., Jubin, R. G., Buontempo, C. A., Wagner, N. E., Reyes, G. R., and
Baroudy, B. M. (2006) Antiviral activity of transiently expressed IFN-kappa is cell-
associated, JInterferon Cytokine Res 26, 40-52.
81. Sheppard, P., W. Kindsvogel, et al. (2003) IL-28, IL-29 and their class II cytokine
receptor IL-28R, Nat Immunol 4, 63-68.
123
82. Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K.,
Langer, J. A., Sheikh, F., Dickensheets, H., and Donnelly, R. P. (2003) IFN-lambdas
mediate antiviral protection through a distinct class II cytokine receptor complex, Nat
Immunol 4, 69-77.
83. Haller, O., G. Kochs, et al. (2007) Interferon, Mx, and viral countermeasures, Cytokine
Growth Factor Rev 18, 425-433.
84. Bach, E. A., Aguet, M., and Schreiber, R. D. (1997) The IFN gamma receptor: a
paradigm for cytokine receptor signaling, Annual review ofimmunology 15, 563-591.
85. Ortaldo, J. R., Herberman, R. B., Harvey, C, Osheroff, P., Pan, Y. C, Kelder, B., and
Pestka, S. (1984) A species ofhuman alpha interferon that lacks the ability to boost
human natural killer activity, Proc NatlAcad Sci USA81, 4926-4929.
86. Young, H. A. (1996) Regulation of interferon-gamma gene expression, JInterferon
Cytokine Res 16, 563-568.
87. Schroder, K., P. J. Hertzog, et al. (2004) Interferon-gamma: an overview of signals,
mechanisms and functions, JLeukoc Biol 75,163-189.
88. Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., Vilcek,
J., Zinkernagel, R. M., and Aguet, M. (1993) Immune response in mice that lack the
interferon-gamma receptor, Science 259,1742-1745.
89. Wallach, D., Fellous, M., and Revel, M. (1982) Preferential effect of gamma interferon
on the synthesis ofHLA antigens and their mRNAs in human cells, Nature 299, 833-836.
90. Mach, B., Steimle, V., Martinez-Soria, E., and Reith, W. (1996) Regulation ofMHC
class II genes: lessons from a disease, Annual review ofimmunology 14, 301-331.
91. Boehm, U., Klamp, T., Groot, M., and Howard, J. C. (1997) Cellular responses to
interferon-gamma, Annual review ofimmunology 15, 749-795.
92. Robek, M. D., Boyd, B. S., and Chisari, F. V. (2005) Lambda interferon inhibits hepatitis
B and C virus replication, J Virol 79, 3851-3854.
93. Ank, N., West, H., Bartholdy, C, Eriksson, K., Thomsen, A. R., and Paludan, S. R.
(2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs
and displays potent antiviral activity against select virus infections in vivo, J Virol 80,
4501-4509.
94. Hiscott, J. (2007) Triggering the innate antiviral response through IRF-3 activation, J
Biol Chem 282, 15325-15329.
124
95. Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N.,
Ohba, Y., Takaoka, A., Yoshida, N., and Taniguchi, T. (2005) IRF-7 is the master
regulator of type-I interferon-dependent immune responses, Nature 434,112-111.
96. Marie, I., Durbin, J. E., and Levy, D. E. (1998) Differential viral induction of distinct
interferon-alpha genes by positive feedback through interferon regulatory factor-7,
EMBO J 17,6660-6669.
97. Munder, M., Mallo, M., Eichmann, K., and Modolell, M. (1998) Murine macrophages
secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18:
A novel pathway of autocrine macrophage activation, The Journal ofexperimental
medicine 187, 2103-2108.
98. Fukao, T., Matsuda, S., and Koyasu, S. (2000) Synergistic effects of IL-4 and IL-18 on
IL-12-dependent IFN-gamma production by dendritic cells, JImmunol 164, 64-71.
99. Golab, J., Zagozdzon, Stoklosal, T., Kaminski, R., Kozar, K., and Jakobisiak, M. (2000)
Direct stimulation ofmacrophages by IL-12 and IL-18~a bridge too far?, Immunology
letters 72, 153-157.
100. Fukao, T., Frucht, D. M., Yap, G., Gadina, M., O'Shea, J. J., and Koyasu, S. (2001)
Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in
innate and adaptive immune responses, JImmunol 166, 4446-4455.
101. Schindler, H., Lutz, M. B., Rollinghoff, M., and Bogdan, C. (2001) The production of
IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is
inhibited by IL-4, JImmunol 166, 3075-3082.
102. Sen, G. C. (2001) Viruses and interferons, Annual review ofmicrobiology 55, 255-281.
103. Cippitelli, M, Sica, A., Viggiano, V., Ye, J., Ghosh, P., Birrer, M. J., and Young, H. A.
(1995) Negative transcriptional regulation of the interferon-gamma promoter by
glucocorticoids and dominant negative mutants of c-Jun, JBiol Chem 270,12548-12556.
104. Xu, X., Sun, Y. L., and Hoey, T. (1996) Cooperative DNA binding and sequence-
selective recognition conferred by the STAT amino-terminal domain, Science 273, 794-
797.
105. Ye, J., Cippitelli, M., Dorman, L., Ortaldo, J. R., and Young, H. A. (1996) The nuclear
factor YYl suppresses the human gamma interferon promoter through two mechanisms:
inhibition ofAPI binding and activation of a silencer element, Mol Cell Biol 16, 4744-
4753.
106. Sica, A., Dorman, L., Viggiano, V., Cippitelli, M., Ghosh, P., Rice, N., and Young, H. A.
(1997) Interaction ofNF-kappaB and NFAT with the interferon-gamma promoter, JBiol
Chem 272, 30412-30420.
125
107. Sweetser, M. T., Hoey, T., Sun, Y. L., Weaver, W. M., Price, G. A., and Wilson, C. B.
(1998) The roles of nuclear factor of activated T cells and ying-yang 1 in activation-
induced expression of the interferon-gamma promoter in T cells, JBiol Chem 273,
34775-34783.
108. Kiani, A., Garcia-Cozar, F. J., Habermann, I., Laforsch, S., Aebischer, T., Ehninger, G.,
and Rao, A. (2001) Regulation of interferon-gamma gene expression by nuclear factor of
activated T cells, Blood 98,1480-1488.
109. Onoguchi, K., Yoneyama, M., Takemura, A., Akira, S., Taniguchi, T., Namiki, H., and
Fujita, T. (2007) Viral infections activate types I and III interferon genes through a
common mechanism, JBiol Chem 282, 7576-7581.
110. Osterlund, P. I., Pietila, T. E., Veckman, V., Kotenko, S. V., and Julkunen, I. (2007) IFN
regulatory factor family members differentially regulate the expression of type III IFN
(IFN-lambda) genes, JImmunol 179, 3434-3442.
111. Wang, J., Oberley-Deegan, R., Wang, S., Nikrad, M., Funk, C. J., Hartshorn, K. L., and
Mason, R. J. (2009) Differentiated human alveolar type II cells secrete antiviral IL-29
(IFN-lambda 1) in response to influenza A infection, JImmunol 182, 1296-1304.
112. Thomson, S. J., Goh, F. G., Banks, H., Krausgruber, T., Kotenko, S. V., Foxwell, B. M,
and Udalova, I. A. (2009) The role of transposable elements in the regulation of IFN-
lambdal gene expression, Proc NatlAcadSci USA 106, 11564-11569.
113. Iversen, M. B., Ank, N., Melchjorsen, J., and Paludan, S. R. (2010) Expression of type III
interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and
displays stronger dependence on NF-kappaB than type I IFNs, J Virol 84, 4579-4586.
114. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Jak-STAT pathways and
transcriptional activation in response to IFNs and other extracellular signaling proteins,
Science 264, 1415-1421.
115. Dile, J. N. (1995) The Janus protein tyrosine kinase family and its role in cytokine
signaling, Advances in immunology 60, 1-35.
116. Fu, X. Y., Schindler, C, Improta, T., Aebersold, R., and Darnell, J. E., Jr. (1992) The
proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene
family involved in signal transduction, Proc Natl Acad Sci USA 89, 7840-7843.
117. Schindler, C, Shuai, K., Prezioso, V. R., and Darnell, J. E., Jr. (1992) Interferon-
dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor, Science
257, 809-813.
126
118. Shuai, K., Schindler, C, Prezioso, V. R., and Darnell, J. E., Jr. (1992) Activation of
transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein,
Science 258, 1808-1812.
119. Silvennoinen, O., Ihle, J. N., Schlessinger, J., and Levy, D. E. (1993) Interferon-induced
nuclear signalling by Jak protein tyrosine kinases, Nature 366, 583-585.
120. Uze, G., Lutfalla, G., and Gresser, I. (1990) Genetic transfer of a functional human
interferon alpha receptor into mouse cells: cloning and expression of its cDNA, Cell 60,
225-234.
121. Pestka, S., Kelder, B., Familletti, P. C, Moschera, J. A., Crowl, R., and Kempner, E. S.
(1983) Molecular weight of the functional unit ofhuman leukocyte, fibroblast, and
immune interferons, JBiol Chem 258, 9706-9709.
122. Darnell, J. E., Jr. (1997) STATs and gene regulation, Science 277, 1630-1635.
123. Donnelly, R. P., and Kotenko, S. V. (2010) Interferon-lambda: a new addition to an old
family, JInterferon Cytokine Res 30, 555-564.
124. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. (1998)
How cells respond to interferons, Annu Rev Biochem 67, 227-264.
125. Noguchi, S., Hijikata, M., Hamano, E., Matsushita, I., Ito, H., Ohashi, J., Nagase, T., and
Keicho, N. MxA transcripts with distinct first exons and modulation of gene expression
levels by single-nucleotide polymorphisms in human bronchial epithelial cells,
Immunogenetics.
126. Fasler-Kan, E., Pansky, A., Wiederkehr, M., Battegay, M., and Heim, M. H. (1998)
Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in
Daudi cells, EurJBiochem 254, 514-519.
127. Matikainen, S., Sareneva, T., Ronni, T., Lehtonen, A., Koskinen, P. J., and Julkunen, I.
(1999) Interferon-alpha activates multiple STAT proteins and upregulates proliferation-
associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells, Blood 93, 1980-1991.
128. Praefcke, G. J., Kloep, S., Benscheid, U., Lilie, H., Prakash, B., and Herrmann, C. (2004)
Identification of residues in the human guanylate-binding protein 1 critical for nucleotide
binding and cooperative GTP hydrolysis, Journal ofmolecular biology 344, 257-269.
129. Haller, O., Stertz, S., and Kochs, G. (2007) The Mx GTPase family of interferon-induced
antiviral proteins, Microbes and infection / Institut Pasteur 9, 1636-1643.
130. Prakash, B., Praefcke, G. J., Renault, L., Wittinghofer, A., and Herrmann, C. (2000)
Structure ofhuman guanylate-binding protein 1 representing a unique class of GTP-
binding proteins, Nature 403, 567-571.
127
131. Low, H. H., and Lowe, J. (2006) A bacterial dynamin-like protein, Nature 444, 766-769.
132. Daumke, O., Lundmark, R., Vallis, Y., Martens, S., Butler, P. J., and McMahon, H. T.
(2007) Architectural and mechanistic insights into an EHD ATPase involved in
membrane remodelling, Nature 449, 923-927.
133. Praefcke, G. J., and McMahon, H. T. (2004) The dynamin superfamily: universal
membrane tubulation and fission molecules?, Nature reviews. Molecular cell biology 5,
133-147.
134. Gao, S., von der Malsburg, A., Paeschke, S., Behlke, J., Haller, O., Kochs, G., and
Daumke, O. Structural basis of oligomerization in the stalk region of dynamin-like MxA,
Nature 465, 502-506.
135. Bourne, H. R., Sanders, D. A., and McCormick, F. (1991) The GTPase superfamily:
conserved structure and molecular mechanism, Nature 349,117-127.
136. Schweins, T., and Wittinghofer, A. (1994) GTP-binding proteins. Structures, interactions
and relationships, Current biology : CB 4, 547-550.
137. Wittinghofer, A. (1998) Signal transduction via Ras, Biological chemistry 379, 933-937.
138. Wittinghofer, A. (1996) Deciphering the alphabet of G proteins: the structure of the
alpha, beta, gamma heterotrimer, Structure 4, 357-361.
139. Sever, S., Muhlberg, A. B., and Schmid, S. L. (1999) Impairment of dynamin's GAP
domain stimulates receptor-mediated endocytosis, Nature 398, 481-486.
140. Janzen, C, Kochs, G., and Haller, O. (2000) A monomeric GTPase-negative MxA
mutant with antiviral activity, J Virol 74, 8202-8206.
141. Marks, B., Stowell, M. H., Vallis, Y., Mills, I. G., Gibson, A., Hopkins, C. R., and
McMahon, H. T. (2001) GTPase activity of dynamin and resulting conformation change
are essential for endocytosis, Nature 410,231-235.
142. Ramachandran, R., Surka, M., Chappie, J. S., Fowler, D. M., Foss, T. R., Song, B. D.,
and Schmid, S. L. (2007) The dynamin middle domain is critical for tetramerization and
higher-order self-assembly, EMBOJ26, 559-566.
143. Vetter, I. R., and Wittinghofer, A. (2001) The guanine nucleotide-binding switch in three
dimensions, Science 294, 1299-1304.
144. Ku, C. C, Che, X. B., Reichelt, M., Rajamani, J., Schaap-Nutt, A., Huang, K. J.,
Sommer, M. H., Chen, Y. S., Chen, Y. Y., and Arvin, A. M. Herpes simplex virus-1
induces expression of a novel MxA isoform that enhances viral replication, Immunol Cell
Biol 89, 173-182.
128
145. Saraste, M., Sibbald, P. R., and Wittinghofer, A. (1990) The P-loop--a common motif in
ATP- and GTP-binding proteins, Trends Biochem Sci 15, 430-434.
146. Milburn, M. V., Tong, L., deVos, A. M., Brunger, A., Yamaizumi, Z., Nishimura, S., and
Kim, S. H. (1990) Molecular switch for signal transduction: structural differences
between active and inactive forms ofprotooncogenie ras proteins, Science 247, 939-945.
147. Kelley, L. A., and Steinberg, M. J. (2009) Protein structure prediction on the Web: a case
study using the Phyre server, Nature protocols 4, 363-371.
148. Lindenmann, J. (1962) Resistance ofmice to mouse-adapted influenza A virus, Virology
16, 203-204.
149. Haller, O., and Lindenmann, J. (1974) Athymic (nude) mice express gene for myxovirus
resistance, Nature 250, 679-680.
150. Horisberger, M. A., Staeheli, P., and Haller, O. (1983) Interferon induces a unique
protein in mouse cells bearing a gene for resistance to influenza virus, Proc Natl Acad Sci
USA80,\9\0-\9\A.
151. Staeheli, P., Haller, O., Boll, W., Lindenmann, J., and Weissmann, C. (1986) Mx protein:
constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective
resistance to influenza virus, Cell 44,147-158.
152. Staeheli, P., Grob, R., Meier, E., Sutcliffe, J. G., and Haller, O. (1988) Influenza virus-
susceptible mice carry Mx genes with a large deletion or a nonsense mutation, Mol Cell
153. Staeheli, P., and Sutcliffe, J. G. (1988) Identification of a second interferon-regulated
murine Mx gene, Mol CellBiol 8, 4524-4528.
154. Staeheli, P., and Haller, O. (1985) Interferon-induced human protein with homology to
protein Mx of influenza virus-resistant mice, Mol CellBiol 5, 2150-2153.
155. Horisberger, M. A., Wathelet, M., Szpirer, J., Szpirer, C, Islam, Q., Levan, G., Huez, G.,
and Content, J. (1988) cDNA cloning and assignment to chromosome 21 of IFI-78K
gene, the human equivalent ofmurine Mx gene, Somatic cell and molecular genetics 14,
123-131.
156. Reeves, R. H., O'Hara, B. F., Pavan, W. J., Gearhart, J. D., and Haller, O. (1988) Genetic
mapping of the Mx influenza virus resistance gene within the region ofmouse
chromosome 16 that is homologous to human chromosome 21, J Virol 62, 4372-4375.
157. Aebi, M., Fah, J., Hurt, N., Samuel, C. E., Thomis, D., Bazzigher, L., Pavlovic, J., Haller,
O., and Staeheli, P. (1989) cDNA structures and regulation of two interferon-induced
human Mx proteins, Mol CellBiol 9, 5062-5072.
129
158. Staeheli, P., Pitossi, F., and Pavlovic, J. (1993) Mx proteins: GTPases with antiviral
activity, Trends CellBiol3, 268-272.
159. Melen, K., Ronni, T., Broni, B., Krug, R. M., von Bonsdorff, C. H., and Julkunen, I.
(1992) Interferon-induced Mx proteins form oligomers and contain a putative leucine
zipper, JBiol Chem 267, 25898-25907.
160. Kochs, G., Haener, M., Aebi, U., and Haller, O. (2002) Self-assembly ofhuman MxA
GTPase into highly ordered dynamin-like oligomers, JBiol Chem 277, 14172-14176.
161. Engelhardt, O. G., Ullrich, E., Kochs, G., and Haller, O. (2001) Interferon-induced
antiviral Mxl GTPase is associated with components of the SUMO-1 system and
promyelocytic leukemia protein nuclear bodies, Exp Cell Res 271, 286-295.
162. Stertz, S., Reichelt, M, Krijnse-Locker, J., Mackenzie, J., Simpson, J. C, Haller, O., and
Kochs, G. (2006) Interferon-induced, antiviral human MxA protein localizes to a distinct
subcompartment of the smooth endoplasmic reticulum, JInterferon Cytokine Res 26,
650-660.
163. Haller, O., and Kochs, G. (2002) Interferon-induced mx proteins: dynamin-like GTPases
with antiviral activity, Traffic 3, 710-717.
164. Netherton, C. L., Simpson, J., Haller, O., Wileman, T. E., Takamatsu, H. H., Monaghan,
P., and Taylor, G. (2009) Inhibition of a large double-stranded DNA virus by MxA
protein, J Virol 83, 2310-2320.
165. Melen, K., Keskinen, P., Ronni, T., Sareneva, T., Lounatmaa, K., and Julkunen, I. (1996)
Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting
signal and is localized in the heterochromatin region beneath the nuclear envelope, JBiol
Chem 277,23478-23486.
166. Haller, O., Staeheli, P., and Kochs, G. (2009) Protective role of interferon-induced Mx
GTPases against influenza viruses, Revue scientifique et technique 28, 219-231.
167. Larsen, R., Rokenes, T. P., and Robertsen, B. (2004) Inhibition of infectious pancreatic
necrosis virus replication by atlantic salmon Mxl protein, J Virol 78, 7938-7944.
168. Kochs, G., and Haller, O. (1999) Interferon-induced human MxA GTPase blocks nuclear
import of Thogoto virus nucleocapsids, Proc Natl Acad Sci USA 96, 2082-2086.
169. Weber, F., Haller, O., and Kochs, G. (2000) MxA GTPase blocks reporter gene
expression of reconstituted Thogoto virus ribonucleoprotein complexes, J Virol 74, 560-
563.
130
170. Reichelt, M., Stertz, S., Krijnse-Locker, J., Haller, O., and Kochs, G. (2004) Missorting
of LaCrosse virus nucleocapsid protein by the interferon-induced MxA GTPase involves
smooth ER membranes, Traffic 5, 772-784.
171. Roers, A., Hochkeppel, H. K., Horisberger, M. A., Hovanessian, A., and Haller, O.
(1994) MxA gene expression after live virus vaccination: a sensitive marker for
endogenous type I interferon, JInfect Dis 169, 807-813.
172. Melen, K., Ronni, T., Lotta, T., and Julkunen, I. (1994) Enzymatic characterization of
interferon-induced antiviral GTPases murine Mxl and human MxA proteins, JBiol Chem
269, 2009-2015.
173. Richter, M. F., Schwemmle, M., Herrmann, C, Wittinghofer, A., and Staeheli, P. (1995)
Interferon-induced MxA protein. GTP binding and GTP hydrolysis properties, JBiol
Chem 270, 13512-13517.
174. Arnheiter, H., Skuntz, S., Noteborn, M., Chang, S., and Meier, E. (1990) Transgenic mice
with intracellular immunity to influenza virus, Cell 62, 51-61.
175. Pavlovic, J., Arzet, H. A., Hefti, H. P., Frese, M., Rost, D., Ernst, B., Kolb, E., Staeheli,
P., and Haller, O. (1995) Enhanced virus resistance of transgenic mice expressing the
human MxA protein, J Virol 69, 4506-4510.
176. Hefti, H. P., Frese, M., Landis, H., Di Paolo, C, Aguzzi, A., Haller, O., and Pavlovic, J.
(1999) Human MxA protein protects mice lacking a functional alpha/beta interferon
system against La crosse virus and other lethal viral infections, J Virol 73, 6984-6991.
177. Pavlovic, J., Zurcher, T., Haller, O., and Staeheli, P. (1990) Resistance to influenza virus
and vesicular stomatitis virus conferred by expression ofhuman MxA protein, J Virol 64,
3370-3375.
178. Schnorr, J. J., Schneider-Schaulies, S., Simon-Jodicke, A., Pavlovic, J., Horisberger, M.
A., and ter Meulen, V. (1993) MxA-dependent inhibition ofmeasles virus glycoprotein
synthesis in a stably transfected human monocytic cell line, J Virol 67, 4760-4768.
179. Frese, M., Kochs, G., Meier-Dieter, U., Siebler, J., and Haller, O. (1995) Human MxA
protein inhibits tick-borne Thogoto virus but not Dhori virus, J Virol 69, 3904-3909.
180. Frese, M., Kochs, G., Feldmann, H., Hertkom, C, and Haller, O. (1996) Inhibition of
bunyaviruses, phleboviruses, and hantaviruses by human MxA protein, J Virol 70, 915-
923.
181. Landis, H., Simon-Jodicke, A., Kloti, A., Di Paolo, C, Schnorr, J. J., Schneider-
Schaulies, S., Hefti, H. P., and Pavlovic, J. (1998) Human MxA protein confers resistance
to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based
replicon in the absence of viral structural proteins, J Virol 72, 1516-1522.
131
182. Schumacher, B., and Staeheli, P. (1998) Domains mediating intramolecular folding and
oligomerization of MxA GTPase, JBiol Chem 273, 28365-28370.
183. Di Paolo, C, Hefti, H. P., Meli, M., Landis, H., and Pavlovic, J. (1999) Intramolecular
backfolding of the carboxyl-terminal end ofMxA protein is a prerequisite for its
oligomerization, JBiol Chem 274, 32071-32078.
184. Zurcher, T., Pavlovic, J., and Staeheli, P. (1992) Mechanism ofhuman MxA protein
action: variants with changed antiviral properties, EMBO J11, 1657-1661.
185. Flohr, F., Schneider-Schaulies, S., Haller, O., and Kochs, G. (1999) The central
interactive region ofhuman MxA GTPase is involved in GTPase activation and
interaction with viral target structures, FEBSLett 463, 24-28.
186. Schwemmle, M., Richter, M. F., Herrmann, C, Nassar, N., and Staeheli, P. (1995)
Unexpected structural requirements for GTPase activity of the interferon-induced MxA
protein, JBiol Chem 270, 13518-13523.
187. Accola, M. A., Huang, B., Al Masri, A., and McNiven, M. A. (2002) The antiviral
dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic
reticulum, JBiol Chem 277, 21829-21835.
188. Kochs, G., Reichelt, M., Danino, D., Hinshaw, J. E., and Haller, O. (2005) Assay and
functional analysis of dynamin-like Mx proteins, Methods in enzymology 404, 632-643.
189. Haller, O., and Kochs, G. Human MxA protein: an interferon-induced dynamin-like
GTPase with broad antiviral activity, JInterferon Cytokine Res 31, 79-87.
190. Mundt, E. (2007) Human MxA protein confers resistance to double-stranded RNA
viruses of two virus families, J Gen Virol 88,1319-1323.
191. Mushinski, J. F., Nguyen, P., Stevens, L. M., Khanna, C, Lee, S., Chung, E. J., Lee, M.
J., Kim, Y. S., Linehan, W. M., Horisberger, M. A., and Trepel, J. B. (2009) Inhibition of
tumor cell motility by the interferon-inducible GTPase MxA, JBiol Chem 284,15206-
15214.
192. Cserny, J. Modulation of chemoresistance in cancer cells with recombinant DNA encoding cell
death regulators Genetics 4.
193. Notani, D., Gottimukkala, K. P., Jayani, R. S., Limaye, A. S., Damle, M. V., Mehta, S.,
Purbey, P. K., Joseph, J., and Galande, S. Global regulator SATB1 recruits beta-catenin
and regulates T(H)2 differentiation in Wnt-dependent manner, PLoS Biol 8, el000296.
194. Notani, D., Limaye, A. S., Kumar, P. P., and Galande, S. Phosphorylation-dependent
regulation of SATB1, the higher-order chromatin organizer and global gene regulator,
Methods Mol Biol 647,317-335.
132
195. Han, H. J., Russo, J., Kohwi, Y., and Kohwi-Shigematsu, T. (2008) SATB1
reprogrammes gene expression to promote breast tumour growth and metastasis, Nature
452, 187-193.
196. Calmon, M. F., Rodrigues, R. V., Kaneto, C. M., Moura, R. P., Silva, S. D., Mota, L. D.,
Pinheiro, D. G., Torres, C, de Carvalho, A. F., Cury, P. M., Nunes, F. D., Nishimoto, I.
N., Soares, F. A., da Silva, A. M., Kowalski, L. P., Brentani, H., Zanelli, C. F., Silva, W.
A., Jr., Rahal, P., Tajara, E. H., Carraro, D. M., Camargo, A. A., and Valentini, S. R.
(2009) Epigenetic silencing of CRABP2 and MX1 in head and neck tumors, Neoplasia
11, 1329-1339.
197. Fernandez, M., Quiroga, J. A., and Carreno, V. (2003) Hepatitis B virus downregulates
the human interferon-inducible MxA promoter through direct interaction of precore/core
proteins, J Gen Virol 84, 2073-2082.
198. Gordien, E., Rosmorduc, O., Peltekian, C, Garreau, F., Brechot, C, and Kremsdorf, D.
(2001) Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein,
J Virol 75, 2684-2691.
199. Muller, M., Brenig, B., Winnacker, E. L., and Brem, G. (1992) Transgenic pigs carrying
cDNA copies encoding the murine Mxl protein which confers resistance to influenza
virus infection, Gene 121, 263-270.
200. Goryachev, A. B., and Pokhilko, A. (2006) Computational Model Explains High Activity
and Rapid Cycling of Rho GTPases within Protein Complexes, PLoS ComputBiol 2.
201. Furuyama, H., Chiba, S., Okabayashi, T., Yokota, S., Nonaka, M., Imai, T., Fujii, N., and
Matsumoto, H. (2006) Single nucleotide polymorphisms and functional analysis ofMxA
promoter region in multiple sclerosis, JNeurol Sci 249, 153-157.
202. Fernandez-Areas, N., Blanco, A., Gaitan, M. J., Nyqvist, M., Alonso, A., and Reyes-
Engel, A. (2004) Differential transcriptional expresion of the polymorphic myxovirus
resistance protein A in response to interferon-alpha treatment, Pharmacogenetics 14,
189-193.
203. Hijikata, M., Mishiro, S., Miyamoto, C, Furuichi, Y., Hashimoto, M., and Ohta, Y.
(2001) Genetic polymorphism of the MxA gene promoter and interferon responsiveness
of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in
vitro, Intervirology 44, 379-382.
204. Hijikata, M., Ohta, Y., and Mishiro, S. (2000) Identification of a single nucleotide
polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of
hepatitis C patients to interferon, Intervirology 43, 124-127.
205. Hamano, E., Hijikata, M., Itoyama, S., Quy, T., Phi, N. C, Long, H. T., Ha, L. D., Ban,
V. V., Matsushita, I., Yanai, H., Kirikae, F., Kirikae, T., Kuratsuji, T., Sasazuki, T., and
133
Keicho, N. (2005) Polymorphisms of interferon-inducible genes OAS-1 and MxA
associated with SARS in the Vietnamese population, Biochem Biophys Res Commun 329,
1234-1239.
206. Torisu, H., Kusuhara, K., Kira, R., Bassuny, W. M., Sakai, Y., Sanefuji, M., Takemoto,
M., and Hara, T. (2004) Functional MxA promoter polymorphism associated with
subacute sclerosing panencephalitis, Neurology 62, 457-460.
207. Nakade, K., Handa, H., and Nagata, K. (1997) Promoter structure of the MxA gene that
confers resistance to influenza virus, FEBS Lett ^75, 315-318.
208. Zhang, J., Wheeler, D. A., Yakub, I., Wei, S., Sood, R., Rowe, W., Liu, P. P., Gibbs, R.
A., and Buetow, K. H. (2005) SNPdetector: a software tool for sensitive and accurate
SNP detection, PLoS ComputBiol 1, e53.
209. Menashe, I., Rosenberg, P. S., and Chen, B. E. (2008) PGA: power calculator for case-
control genetic association analyses, BMC Genet 9, 36.
210. zur Hausen, H. (2002) Papillomaviruses and cancer: from basic studies to clincial
application, Nat. Rev. Cancer, 342-350.
211. Hong Shiyuan, K. P. M., and Laimoni A. Laimins. (2011) Suppression of STAT-1
Expression by Human Papillomaviruses Is Necessary for Differentiation-Dependent
Genome Amplification and Plasmid Maintenance, Virol J 85, 9486-9494.
212. Cao, B., Liu, X., Hou, F., Li, W., Han, Z., Zhang, Q., Dai, Y., Xu, C, and Qi, H. (2009)
The haplotype of the MxA gene promoter is associated with hepatitis B virus infection in
a Chinese population, Liver Int 29, 1383-1388.
213. Ching, J. C, Chan, K. Y., Lee, E. H., Xu, M. S., Ting, C. K., So, T. M., Sham, P. C,
Leung, G. M., Peiris, J. S., and Khoo, U. S. Significance of the myxovirus resistance A
(MxA) gene -123C>a single-nucleotide polymorphism in suppressed interferon beta
induction of severe acute respiratory syndrome coronavirus infection, JInfect Dis 201,
1899-1908.
214. Horisberger, M. A., and M. C. Gunst. (1991) Interferon-induced proteins: Identification
ofMx proteins in various mammalian species, Virology 180, 185-190.
215. Ott, T. L., Yin, J., Wiley, A. A., Kim, H. T., Gerami-Naini, B., Spencer, T. E., Bartol, F.
F., Burghardt, R. C, and Bazer, F. W. (1998) Effects of the estrous cycle and early
pregnancy on uterine expression ofMx protein in sheep (Ovis aries), Biology of
reproduction 59, 784-794.
216. Racicot, K., and Ott, T. (2011) The myxovirus resistance protein, MX1, interacts with
tubulin beta in uterine glandular epithelial cells, Am JReprod Immunol 65, 44-53.
134
217. Shou, J., Soriano, R., Hayward, S. W., Cunha, G. R., Williams, P. M., and Gao, W. Q.
(2002) Expression profiling of a human cell line model of prostatic cancer reveals a direct
involvement of interferon signaling in prostate tumor progression, Proc Natl Acad Sci U
SA 99, 2830-2835.
218. Nagano, K., Masters, J. R., Akpan, A., Yang, A., Corless, S., Wood, C, Hastie, C,
Zvelebil, M., Cramer, R., and Naaby-Hansen, S. (2004) Differential protein synthesis and
expression levels in normal and neoplastic human prostate cells and their regulation by
type I and II interferons, Oncogene 23, 1693-1703.
219. Schulz, W. A., Alexa, A., Jung, V., Hader, C, Hoffmann, M. J., Yamanaka, M.,
Fritzsche, S., Wlazlinski, A., Muller, M., Lengauer, T., Engers, R., Florl, A. R., Wullich,
B., and Rahnenfuhrer, J. (2007) Factor interaction analysis for chromosome 8 and DNA
methylation alterations highlights innate immune response suppression and cytoskeletal
changes in prostate cancer, Mol Cancer 6,14.
220. Glymph, S., Mandal, S., Knowell, A. E., Abebe, F., and Chaudhary, J. (2013) The
Myxovirus Resistance A (MxA) Gene -88G>T Single Nucleotide Polymorphism Is
Associated with Prostate Cancer, Infection, genetics and evolution : journal ofmolecular
epidemiology and evolutionary genetics in infectious diseases.
221. Khandelwal, P., Liu, S., and Sullivan, D. A. (2012) Androgen regulation of gene
expression in human meibomian gland and conjunctival epithelial cells, Molecular vision
18,1055-1067.
222. Masamha, C. P., and Benbrook, D. M. (2009) Cyclin Dl degradation is sufficient to
induce Gl cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer
cells, Cancer Res 69, 6565-6572.
223. Yoshida, T., Zhang, Y., Rivera Rosado, L. A., Chen, J., Khan, T., Moon, S. Y., and
Zhang, B. (2010) Blockade of Racl activity induces Gl cell cycle arrest or apoptosis in
breast cancer cells through downregulation of cyclin Dl, survivin, and X-linked inhibitor
of apoptosis protein, Molecular cancer therapeutics 9, 1657-1668.
224. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V.,
and Bates, S. E. (2000) P21-dependent g(l)arrest with downregulation of cyclin Dl and
upregulation of cyclin E by the histone deacetylase inhibitor FR901228, Britishjournal
ofcancer 83, 817-825.
225. Wikipedia. (2013) G2 phase.
226. Brouty-Boye, D., and Zetter, B. R. (1980) Inhibition of cell motility by interferon,
Science 208, 516-518.
227. Tan, T. W., Yang, W. H., Lin, Y. T., Hsu, S. F., Li, T. M., Kao, S. T., Chen, W. C, Fong,
Y. C, and Tang, C. H. (2009) Cyr61 increases migration and MMP-13 expression via
135
alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human
chondrosarcoma cells, Carcinogenesis 30, 258-268.
228. Yu, T., Wu, Y., Helman, J. I., Wen, Y., Wang, C, and Li, L. (2011) CXCR4 promotes
oral squamous cell carcinoma migration and invasion through inducing expression of
MMP-9 and MMP-13 via the ERK signaling pathway, Molecular cancer research : MCR
9,161-172.
229. Solimini, N. L., Liang, A. C, Xu, C, Pavlova, N. N., Xu, Q., Davoli, T., Li, M. Z.,
Wong, K. K., and Elledge, S. J. (2013) STOP gene Phactr4 is a tumor suppressor, Proc
NatlAcadSci USA 110, E407-414.
230. Dreijerink, K., Braga, E., Kuzmin, I., Geil, L., Duh, F. M., Angeloni, D., Zbar, B.,
Lerman, M. I., Stanbridge, E. J., Minna, J. D., Protopopov, A., Li, J., Kashuba, V., Klein,
G., and Zabarovsky, E. R. (2001) The candidate tumor suppressor gene, RASSF1A, from
human chromosome 3p21.3 is involved in kidney tumorigenesis, Proc Natl AcadSci US
A 98, 7504-7509.
231. Okahara, F., Itoh, K., Nakagawara, A., Murakami, M., Kanaho, Y., and Maehama, T.
(2006) Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol
3,4,5-trisphosphate signals and tumorigenic transformation, Molecular biology ofthe cell
77,4888-4895.
232. Horisberger, M. A. (1992) Interferon-induced human protein MxA is a GTPase which
binds transiently to cellular proteins, J Virol 66, 4705-4709.
233. Abal, M., Piel, M., Bouckson-Castaing, V., Mogensen, M., Sibarita, J. B., and Bornens,
M. (2002) Microtubule release from the centrosome in migrating cells, The Journal of
cell biology 159,131-731.
234. Magdalena, J., Millard, T. H., and Machesky, L. M. (2003) Microtubule involvement in
NIH 3T3 Golgi and MTOC polarity establishment, J Cell Sci 116, 743-756.
235. Lafont, F., Burkhardt, J. K., and Simons, K. (1994) Involvement ofmicrotubule motors in
basolateral and apical transport in kidney cells, Nature 372, 801-803.
236. Yvon, A. M., Wadsworth, P., and Jordan, M. A. (1999) Taxol suppresses dynamics of
individual microtubules in living human tumor cells, Molecular biology ofthe cell 10,
947-959.
237. What is prostate cancer,
http://www.cancer.org/cancer/prostatecancer/overviewguide/prostate-cancer-overview-
what-is-prostate-cancer
238. How to Detect Prostate Cancer Signs or Sympotoms, http://www.prl0g.0rg/l 1415250-
how-to-detect-prostate-cancer-signs-or-symptoms.html
136
239. Parham, P. The Immune System, 3 ed., https://www.inkling.com/read/the-immune-
system-peter-parham-3rd/chapter-2/figure-2-44.
240. Heim, M. H. (2012) Interferons and hepatitis C virus, Swiss medical weekly 142, wl3586.
241. Stubgen, J. P. (2009) Recombinant interferon-beta therapy and neuromuscular disorders,
JNeuroimmunol 212, 132-141.
242. Haller, O., Gao, S., von der Malsburg, A., Daumke, O., and Kochs, G. Dynamin-like
MxA GTPase: structural insights into oligomerization and implications for antiviral
activity, JBiol Chem 285, 28419-28424.
243. Haller, O. Mx Proteins: Large GTPases Involved in Host Defense against RNA viruses in
http://www. uniklinik-
freiburg.de/virologie/live/forschung/teams/hallerteam/MxProteins_en.html?raw=true.
244. Daumke, O., Gao, S., von der Malsburg, A., Haller, O., and Kochs, G. (2010) Structure
ofthe MxA stalk elucidates the assembly of ring-like units of an antiviral module, Small
GTPases 1, 62-64.
245. NCBI. Reference SNP(refSNP) Cluster Report: rs2071430,
https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2071430
246. Reporter: GPL83OO, a. I. R., GDS2545,4599 (Gene ID), M33882. in
https://www.ncbi.nlm.nih.gov/geo/tools/profileGraph.cgi?ID=GDS2545:37014_at((HG-
U95A), M. p. c, Ed.).
247. Database, O. Normal Prostate vs. Prostate Cancer,
https://www.oncomine.org/resource/main.html#a%3A1879%3Bd%3A32%3Bdso%3Age
neUnderex%3Bdt%3ApredefinedClass%3Bec%3A[2%2Cl]%3Bepv%3A150001.15107
8%2C3508%3Bet%3Aunder%3Bf%3A2497875%3Bg%3A4599%3Bgt%3Aboxplot%3B
p%3A200001311%3Bpg%3Al%3Bpvf%3A3483%2C28707%2C150004%3Bscr%3Adat
asets%3Bss%3Aanalysis%3Bth%3Agl0.0%2Cp0.010%2Cfc2.0%3Bv%3A15.
